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Chapter 1: A Review of Synthesis and Screening Peptide Libraries with Free 
C-termini 
 
1.1 Introduction to peptide library synthesis 
(a) Solid-phase peptide synthesis 
Combinatorial synthesis has been one of the most rapidly developing fields in the 
academic laboratory and pharmaceutical industry in the past two decades and is now 
seen as an essential tool in both the discovery and the development of new bioactive 
molecules and drugs. Put at its simplest, combinatorial synthesis is a means of 
producing a large number of compounds in a short period of time, using a defined 
reaction route and a large variety of starting materials and reagents. Usually, this is 
done on a small scale using solid phase synthesis, so that the process can be 
automated or semi-automated. This allows each reaction of the synthetic route to be 
carried out in several reaction vessels (or spots) at the same time and under identical 
conditions, but using different reagents for each vessel (or each spot). 
Solid phase synthesis was pioneered for the synthesis of peptides, and most of 
the early work carried out on combinatorial synthesis was performed on peptides as 
well because the building blocks (amino acids) have some regular functionalities 
(amino group and carboxylic acid group). There are already 20 amino acids available 
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from Nature meaning that there are already many building blocks to generate mixtures, 
which will be referred to combinatorial libraries in this manuscript. For example, if a 
library of tetrapeptides is to be synthesized with 20 variations for each amino acid, a 
mixture of 204 = 1.6×105 kinds of peptides will be obtained at the end. If unnatural 
amino acids are incorporated for library build-up, a library of bigger size will be 
generated. Peptide libraries will be the focus of this manuscript. 
The idea of chemical synthesis of peptides is that the first amino acid is attached 
to a solid support through its carboxyl group and then each N-protected amino acid is 
added in turn. During the coupling, the carboxyl group of the new coming amino acid 
must be activated. The commonly used activating reagents are a carbodiimide (for 
example, DIC), a uranium (for example, HCTU) or a phosphonium (for example, 
BOP) (Figure 1.1). After each addition, the N-protection must be removed before the 
next amino acid is added. The commonly used N-protecting group is Fmoc which can 
be removed under basic condition such as 20% piperidine so this process is also called 
Fmoc-solid phase peptide synthesis (Fmoc-SPPS). The growing peptide chain is 
attached to the solid support so that all waste products, removed protecting groups, 
excess reagents and inorganic rubbish can be washed out after each operation. 
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Figure 1.1 A schematic view of Fmoc-solid phase peptide synthesis. 
 
Combinatorial synthesis can be carried out such that a single product is obtained 
in each different reaction flask—a process known as parallel synthesis. Alternatively, 
the process can be designed such that mixtures of compounds are produced in each 
reaction vessel. 
Parallel synthesis can be performed on resins which is a cross-linked insoluble 
polymeric bead or on pieces of chemically functionalized papers which will be 
referred to membranes in this manuscript. One manual approach to parallel synthesis 
is called teabag procedure.1 The polymeric support resin is sealed in labeled meshed 
containers (known as teabags). The teabags are then placed in bottles which act as the 
reaction vessels (Figure 1.2). In the case of a peptide synthesis, the first amino acid is 
added to the resin (different amino acids for different bottles). All teabags in one 
specific bottle now have the same amino acid linked to the resin. The teabags from 
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every bottle are now combined in one vessel for deprotection and washing. The 
teabags can then be redistributed between the bottles for the addition of a second 
amino acid, recombined for deprotection and washing, redistributed for addition of 
the next amino acid, and so on. 
 
 
Figure 1.2 Teabag procedure. 
 
Another approach to parallel synthesis is called SPOT synthesis. In SPOT 
synthesis, the solutions of activated amino acids are positionally addressed and 
delivered in small drops to distinct points on the solid surface such as functionalized 
cellulose membrane or glass forming a pattern of small spots. Peptides arrays are 
synthesized in a stepwise manner following the standard Fmoc-based peptide 
chemistry (Figure 1.3).2 Using the automated SPOT synthesis, it is routine to 
synthesize and screen 600 peptides on the membrane of 10×15 cm2 size. 
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Figure 1.3 A schematic view of the SPOT synthesis and their applications in the binding 
assays.  
 
The disadvantage of the parallel synthesis is that the resulting library has a small 
size — within 1000 members is usually made each time. If a bigger library is to be 
synthesized, the split and mix method should be a better choice. The solid phase of 
split and mix method is a resin (bead). The split and mix method consists of three 
steps3: (1) Each amino acid is coupled to resin beads. (2) The beads are mixed 
together and separated into equal portions. The number of portions depends on how 
many residues are going to be coupled. Then each portion is reacted with a different 
amino acid. (3) Repeat the process of (1) and (2). All beads are mixed together and 
split into portions. Each portion is reacted with one of the building amino acids 
(Figure 1.4). In Figure 1.4, we have three amino acids (Gly, Ala and Val) as our 
building blocks and we want to make a tripeptide library. After the split and mix 
synthesis, we will get all 27 possible tripeptides. Synthesis and screening of longer 
peptides is routine nowadays. If we have 20 amino acids and we want to make a 
 6
pentapeptide library, a library size of 205 = 3.2×106 members will be generated. The 
size is much bigger than what could be made by parallel synthesis. However, in this 
case you have a mixture of compounds in a vessel. Note that in the split and mix 
method, each bead has a unique peptide sequence attached to it so the resulting library 
is also called one-bead-one-compound (OBOC) library. After screening the bead 
library, the peptide sequences from the selected beads can be determined by Edman 
degradation,4 partial Edman degradation—mass spectrometry (PED/MS)5 or tandem 
mass spectrometry (MS/MS).6 
 
 
Figure 1.4 A schematic view of the split and mix method (or OBOC method). 
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(b) Phage display 
In contrast to solid-phase peptide synthesis, in biological systems a peptide or 
protein is synthesized from its N-terminal end to its C-terminal end. In cells the 
genetic message is transcribed from DNA into RNA and then translated into protein. A 
sequence of three nucleotide bases, called a codon, specifies a particular amino acid 
that is to be incorporated into a protein. Each amino acid is specified by a three-base 
sequence and this relationship is known as the genetic code. For example, UCA on 
mRNA codes for the amino acid serine, while CAG codes for glutamine. Since in 
nature the protein sequence is determined by DNA sequence, the problem of how to 
make peptide libraries is actually the problem of how to make DNA libraries. There 
are several ways of making DNA libraries. First, degenerate DNA primers can be 
synthesized by solid-phase synthesis. For example, if a random nonapeptide is to be 
attached to the C-terminus of a protein, a primer sequence containing (NNK)9 can be 
made and incorporated at the C-terminus of the protein (Figure 1.5). N stands for any 
of the 4 nucleotides (A, T, C, G) and K stands for G or T. The reason why NNK 
sequences for random codons are used instead of NNN is because we want the chance 
of random codons happening to be stop codons minimized. The codons for the 20 
amino acids are still retained in the NNK codons. 
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Figure 1.5 Illustration of making a random DNA library by the use of degenerate primer 
(primer 1). 
 
If we want a library of certain sequences, for example DNA sequences present in 
human genome, a completely random DNA library may not be the optimal choice. 
Customized DNA microarray can be ordered. In this case, Oligonucleotides encoding 
sequences of interest are generated and linked on a microarray slide. The sequences 
can be amplified by PCR and then cloned into a vector, for example, a phagemid 
(Figure 1.6). 
 
A designed DNA library
ssDNA microarray
PCR
dsDNA mixture
cloning and
phage library
construction
Phage library  
Figure 1.6 A procedure of making a customized DNA library. 
 
A piece of DNA sequence can be randomized by error-prone PCR. In this 
method, during PCR not only dNTP are added to the solution, but also mutagenic 
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nucleotides like 8-oxo-2’-deoxyguanosine (8-oxo-dGTP) and 
4-dihydro-8H-pyrimido[4,5-c][1,2]oxazine-7-one (dPTP) are added. During DNA 
replication, the mutagenic nucleotides can mispair with the base of the opposite strand 
to cause mutations. The rate of mutagenesis can be controlled by the number of PCR 
cycles and the concentration of mutagenic nucleotides. 
Phage display is a method of identifying peptides, which can be recognized by a 
target such as a receptor or an enzyme, from a library. Phage display depends on the 
fact that the phages are made up of DNA coated with proteins encoded by that DNA. 
If a particular peptide sequence is translationally fused to the coding sequence for one 
of the coat proteins of the phage, all the progeny of that phage will display the 
particular peptide sequence on their surface. To use this technology, a randomized 
peptide-coding sequence is fused to a coat protein so that different phages display 
different versions of the peptide on their surface. The phage that displays a version of 
the peptide which binds to the target are “panned for” and isolated. If only a few 
phage particles from the mixture can be separated from most of other phages that 
express different peptides, the phages can be propagated to make hundreds of millions 
of identical copies. The cloned DNA can then be sequenced to determine the 
particular peptide sequence which binds to the target (Figure 1.7). Many different 
types of phages have been adapted for phage display. In some cases, different coat 
 10
proteins from a phage can be chosen to display the peptides. Which phage and which 
coat protein to use depend on the specific application. 
 
cloning and
phage library construction
DNA libraries of peptides Phage library
binding selection
immobilized target
elute
wash
amplify
new selection round
sequence analysis
 
Figure 1.7 Schematic procedure of phage display. 
 
1.2 Synthesis and screening of C-terminal peptide library 
(a) Interactions involving peptides with C-termini 
Protien-protein interactions and protein post-translational modifications 
participate in a wide range of cellular process such as the control of protein 
localization, protein turn-over, enzyme activity and regulation of signal transduction. 
Misregulation of protein-protein interactions and post-translational modifications 
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often involve in many diseases such as cancers highlighting their importance in cell 
physiology. Among these interactions, some proteins bind to their partners at the 
C-terminus. The PDZ domain (acronym of the synapse-associated protein 
PSD-95/SAP90, the septate junction protein Discs-large and the tight junction protein 
ZO-1) is one of the most common protein modules in eukaryotic cells. These domains 
bind C-terminal motifs of target proteins. It is documented that the last four amino 
acids in the C-terminal targets are of crucial importance in determining PDZ domain 
affinity. The residue selectivity in these positions is commonly used to distinguish 
peptide ligands into classes.7,8 For example, S/T-X-Ψ is for class I, Φ-X-Ψ for class II, 
and E/D-X-Ψ for class III with Ψ and Φ represent aliphatic and hydrophobic amino 
acids, respectively. Other classes of peptides recognized by different PDZ domains 
were also reported.9-11 Some proteins harbor multiple PDZ domains that are often 
arranged in closely linked groups. This renders the proteins capable of binding to 
several different transmembrane or intracellular partners at the same time, thus 
organizing multimeric complexes.  
Neurophilin-1 (NRP-1) is another example of proteins recognizing the C-termini 
of their partners. NRP-1 is a cell-surface receptor that plays an important role in 
angiogenesis and cardiovascular development.12,13 NPR-1 mediates vascular 
permeability induced by VEGF and certain semaphorins.14,15 NPR-1 interacts with 
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VEGF and semaphoring 3A through their C-terminal basic residues. Several peptides 
homologous to the VEGF C-terminus are known to compete with VEGF-NPR-1 
interaction.16,17 
After a protein is synthesized, the structure can be modified by other enzymes. 
For example, a protein can be cleaved by a protease, phosphorylated by a kinase or 
lipidated by a prenyltransferase. This process is called post-translational modification. 
The purpose of post-translational modification is to switch on (or switch off) an 
enzyme’s activity, to locate the protein to certain place in the cell or to change the 
binding affinity to other proteins. Some enzymes carrying out such reactions 
recognize C-termini of their substrates. For example, prenylation of a variety of 
proteins with isoprenoid is essential for normal cellular functions and has important 
roles in numerous diseases. Protein prenylation involves the addition of farnesyl (C15) 
or geranylgeranyl (C20) isoprenoids near the C-termini of proteins and is catalyzed by 
protein farnesyltransferase (PFTase) and geranylgeranyltransferases (GGTase), 
respectively.18 In a previous model, the enzymes recognize a C-terminal tetrapeptide 
sequence called Ca1a2X motif where C is the cysteine to which the isoprenoid is 
attached, a1 and a2 are usually aliphatic amino acids and X is the major determinant 
for modification by either PFTase or GGTase I (Figure 1.8).19,20 
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Protein-CaaX-OH
SH
farnesylation
Protein-CaaX-OH
S
 
Figure 1.8 C-terminal farnesylation. 
 
Connecting proteins to ubiquitins (Ubs) is another modification associated with a 
variety of cellular functions, including regulation of protein degradation, control of 
protein subcellular localization, induction of protein-protein interactions and 
regulation of enzymatic activities. Ubiquitin is a 76-residue protein that can be linked 
to other cellular proteins through an isopeptide bond between the C-terminal 
carboxylate of Ub and the ε-amino group of a Lys residue on the modified protein.21 
The Ub modification pathway involves three enzymes, E1, E2, E3. The E1 enzyme 
catalyzes the attachment of Ub molecule to a Cys residue of E1 itself to form a Ub-E1 
thioester bond. Next, Ub is transferred to an E2 to form a Ub-E2 conjugate via a 
trans-thioester reaction. Finally an E3 enzyme catalyzed the transfer of Ub from E2 to 
the substrate protein (Figure 1.9).22 So far, there are 2 E1s, 50 E2s and more than 
1000 E3s identified in the human genome.23,24 These enzymes assemble overlapping 
and intersecting networks for Ub transfer to the cellular target proteins. 
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Figure 1.9 The enzymatic cascade of E1-E2-E3 that catalyzes Ub transfer onto substrate 
proteins. 
 
There are nearly 20 structurally Ub-related proteins in eukaryotes such as Nedd8 and 
SUMO. These proteins are called ubiquitin-like proteins (UBLs). Although 
structurally related, UBLs regulate a strikingly diverse set of cellular processes, 
including nuclear transport, proteolysis, translation, autophagy, and antiviral 
pathways.25 The UBL modification involves similar E1-E2-E3 cascade. Several 
proteins involved in these ubiquitin-related processes need to specifically recognize 
Ub or UBL to perform their function, such as deubiquitylation enzymes (DUBs), 
certain trafficking proteins and ubiquitin conjugating enzymes. To recognize Ub or 
UBL, many proteins utilize a variety of ubiquitin-binding domains.26 Some domains, 
like BUZ domain, have been found to interact with ubiquitin by binding to its free 
C-terminus.27,28  
Not only there are examples of proteins recognizing C-terminal peptides, but also 
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some peptide analogues can bind to their targets at their C-termini. Vancomycin is a 
narrow-spectrum antibiotic produced by a bacterium Streptomyces orientalis. 
Vancomycin is derived biologically from a linear heptapeptide containing 5 aromatic 
residues. Oxidative coupling, chlorination, hydroxylation and final addition of two 
sugars complete the structure (Figure 1.10). There is a pocket in the vancomycin 
structure into which the tail of the bacterial cell wall building block’s pentapeptide 
moiety can fit. It is held there by the formation of five hydrogen bonds between the 
cell wall building block and vancomycin (Figure 1.10). Because vancomycin is a 
large molecule, it covers the tails and acts as a steric shield, blocking access to the 
transglycosidase and transpeptidase enzymes for cell wall construction.29 
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Figure 1.10 Vancomycin and binding interactions to the L-Lys-D-Ala-D-Ala moiety. 
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(b) Solid-phase peptide synthesis 
The well-established solid-phase peptide synthesis starts from C-terminus to 
N-terminus. The C-terminus of the peptide is tethered to the solid support (Figure 1.1). 
This technical problem makes the determination of the sequence specificity of targets 
which require free C-termini for recognition difficult. One way to solve this problem 
is to make peptides on solid phase but then release the peptides and performed the 
screening assays in solution. Spaller and coworkers made two chemical libraries of 
hexapeptide YKQTXV template in a parallel synthesis platform with 92 variations of 
X in the library I and 186 variations of X in the library II.30 Resins were arrayed into 
96-well filter plate. After the peptides were cleaved from the beads, an ELISA-type 
assay was used to screen the binding of peptides to third PDZ domain (PDZ3) of 
PSD-95 protein (Figure 1.11). 
 
 
Figure 1.11 Synthesis and screening of C-terminal-displayed organic acid-modified 
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libraries for PSD-95 PDZ3. Reagents and conditions: (a) Solid-phase peptide synthesis; (b) 
linker coupling; (c) biotinylation; (d) Dde removal (2% hydrazine); (e) array resin into 
96-well filter plates and couple to a variety of organic acids (R’CO2H); (f) TFA treatment. 
 
Cantley and coworkers used a similar approach to investigate the peptide-binding 
specificities of nine PDZ domains from various proteins.7 A primary library, 
KNXXXXXXXX-COOH, and a secondary library, KNXXXXXX(S,T,Y)XX-COOH, 
were made by split and mix method. The peptides were released into solutions as a 
mixture. Some peptides with affinity to a PDZ domain were enriched and then 
sequenced by Edman degradation. Since a peptide pool was sequenced at the same 
time, preference for certain amino acids at a given position was obtained, not the 
individual binding sequences. The above approaches used off-bead screening platform 
meaning that the peptides are not attached to the solid phase when they are tested for 
biological activity. However, there are two disadvantages for off-bead screening. First, 
the off-bead screening is usually slower than on-bead screening. In the on-bead 
screening platform, 108 beads can be readily screened which is faster than the 96-well 
plate format in the first example. Second, there are cases where the peptides released 
prove to be insoluble in the test assay and give a false-negative result which could be 
avoided if the peptides were attached to the bead during the assay. 
If on bead screening is to be performed, some ingenuity is going to be taken to 
present a free carboxyl terminus for target recognition because in a standard 
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solid-phase peptide library, the carboxyl terminus of the peptide is tethered to the 
solid support. Many researchers have prepared peptide libraries with free C-termini by 
a method called “peptide inversion” (Figure 1.12). In this approach, a peptide is first 
synthesized in the conventional C to N manner. However, during this synthesis, a 
special handle is installed. This special moiety contains two functional groups (FG 1 
and FG 2). Peptide synthesis continues on FG 1 in the traditional C to N manner. Next, 
the complete peptide (AAn—AA1) is cyclized between its N-terminus and the internal 
FG 2 to give a cyclic peptide. Note that the N-terminus of the complete peptide can be 
an exposed amino group or another functional group installed (FG 3 in Figure 1.12). 
Finally, cleavage of the cyclic peptide from C-terminus of AA1 releases the free 
C-terminus for screening. 
 
H2N handle
FG 1
FG 2
Fmoc-SPPS
handle
AA1
FG 2
AAn
handle
AA1
FG 3
AA2
AAn
handle
FG 1
AAnAA1HOOC
cyclization
ring cleavage
 
Figure 1.12 Illustration of peptide inversion strategy, a method of Synthesis of 
C-terminal libraries. 
 
Marlowe can coworkers used this strategy to make resin-bound peptides with 
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free C-termini (Figure 1.13).31 Note that in the structure 1.1 during their synthesis, the 
HMPA-Lys-Suc is the special handle in Figure 1.12. The HMPA is the FG 1 and Suc 
is the FG 2 which is protected by o-nitrobenzyl group. Peptide synthesis continues 
from HMPA and the bond between the first amino acid to the HMPA is an ester bond. 
After the peptide is complete, o-nitrobenzyl group is removed by UV light to expose 
the free carboxylic acid (FG 2). Intramolecular amide bond formation generates a 
cyclic peptide. The ether bond between the peptide and HMPA is labile in acidic 
condition because of the electron-donating oxygen atom directly attached to the 
phenyl ring. Under 95% TFA, the ether bond between peptide and HMPA is cleaved 
to give a peptide with C-terminus exposed and N-terminus attached to the surface. 
Later, those peptides can be processed by carboxypeptidase Y to release the 
C-terminal 4 amino acids into solutions. 
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Figure 1.13 Synthesis of resin-bound peptides with free C-termini and enzymatic 
analysis. Reagents and conditions: (a)Fmoc-Lys(Boc)-OH, DIC, HOBt, CH2Cl2; (b) 50% TFA 
/ CH2Cl2; (c) o-NO2BnSuc, DIC, HOBt, DMF; (d) 20% piperidine / DMF; (e) HMPA-OPfp, 
DIEA, DMF; (f) Fmoc-Amino acid, DIC, HOBt, DMAP, DMF; (g) Solid-phase peptide 
synthesis; (h) hv at 360 nm, 5% NH4OH; (i) BOP, DIEA, DMF; (j) 5% anisole, 5% 
ethanedithiol, 90% TFA. 
 
If peptide libraries are made by the above example, a problem occurs. How do 
we determine the peptide sequences from the mixtures of beads? Edman degradation 
is a common way to characterize peptide sequences. However, Edman degradation 
requires peptides with free N-termini. This problem is avoided if parallel synthesis is 
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adopted. For example, in SPOT synthesis, the peptide sequences are known based on 
the locations of spots on a membrane. Volkmer and coworkers used SPOT synthesis to 
analyze PDZ domain regulation mechanisms (Figure 1.14).32 In their synthetic 
method, the Cys-βAla-HMPA in structure 1-2 is the special handle shown in Figure 
1.12. The HMPA is the FG 1 and Cys is the FG 2 which is protected by trityl group. 
Peptide synthesis continues from HMPA and the bond between the first amino acid to 
the HMPA is an ester bond. The traditional esterification methods are not compatible 
with SPOT synthesis format due to the long reaction time and volatility of the solvent 
(CH2Cl2 is usually the solvent). They previously developed a new ester bond 
formation method utilizing CDI (1,1’-carbonyldiimidazole) as the activating reagent 
for amino acid coupling.33 The reaction time and conditions have been optimized for 
SPOT synthesis. CDI was replaced by CDT (1,1’-carbonyl-di-(1,2,4-triazole)) as an 
activator when the amino acids are Gln, Tyr or Pro to avoid a precipitation problem 
(step b in Figure 1.14). After the peptide is complete, the N-terminus is reacted with 
bromoacetic acid. The resulting bromoacetamide is a reactive electrophile (FG 3 in 
Figure 1.12) which can react with the deprotected Cys under mild basic condition to 
form a cyclic peptide. Then the peptides with free C-termini can be generated by TFA 
treatment because of the lability of the ether bond between the HMPA and the amino 
acid 1. The use of Cys as the nucleophilic FG 2 meaning that Cys cannot be 
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incorporated in the peptide library synthesis but the use of orthogonally protected 
Cys34,35 should solve this problem. 
 
 Figure 1.14 Synthesis of peptides with free C-termini by SPOT synthesis for PDZ binding 
assay. Reagents and conditions: (a) Standard Fmoc-SPPS, β-Ala, Cys(Trt), β-Ala, HMPA; (b) 
Fmoc-Amino acid, CDI, DMF (the CDI is replaced by CDT when the amino acids are Gln, 
Tyr or Pro); (c) Standard Fmoc-SPPS; (d) bromoacetic acid 2,4-dinitrophenyl ester, NMP; (e) 
7% TFA, CH2Cl2; (f) Cs2CO3 / H2O / DMF; (g) 60% TFA followed by 90% TFA. 
  
Volkmer and coworkers determined the specificity of PDZ domains by 
incubating the membrane in a solution containing PDZ domains with GST fusion. The 
high affinity peptides were detected by the use of anti-GST antibody with HRP 
fusion.32,36,37 Later they used a similar strategy to find candidate substrates of a 
periplasmic protease containing PDZ domains (Tsp) from E. coli.38 648 proteins were 
found to be potential substrates based on bioinformatic analysis. Their C-terminal 
sequences were generated by SPOT synthesis (Figure 1.14). The resulting membrane 
was incubated with a His-tagged Tsp solution. The protease Tsp was made inactive by 
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mutating Ser at 430 to Ala to prevent proteolytic degradation of the immobilized 
peptides. Following incubation, bound Tsp was identified by the use of an anti-His 
antibody. This screen identified 24 candidate proteins that potentially interact with 
Tsp.38 
Distefano’s group adopted a similar approach to make peptide libraries with free 
C-termini by SPOT synthesis (Figure 1.15).39,40 In their synthetic scheme, the 
HMPA-Glu-ODmab in structure 1-3 is the special handle shown in Figure 1.12. The 
HMPA is the FG 1 and the carboxylic acid side chain of Glu is the FG 2 which is 
protected by Dmab group. Peptide synthesis continues from HMPA. The N-terminal 
amino group of the peptide library is protected by Dde group which can be removed 
along with Dmab group at the same time by hydrazine. The N-terminal amino group 
and the internal carboxylic acid group are exposed. An intramolecular amide bond 
formation results in a cyclic peptide. The peptide libraries with free C-termini can be 
generated by TFA treatment because of the lability of the ether bond between the 
HMPA and the amino acid X. Note that a photocleavable molecule is incorporated 
into the peptide synthesis. The purpose of the photocleavable molecule is to release 
peptides from the membrane by photolysis and be analyzed by MALDI to make sure 
the library synthesis works fine. They made 20X19 RAGCVa2X and RAGCCa2X 
libraries with the X being one of the 20 proteogenic amino acids except Pro and a2 
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being one of the 20 proteogenic amino acids.  
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Figure 1.15 Synthesis of inverted peptides for screening assay. Reagents and conditions: 
(i) standard DIC coupling, then, capping, then 20% piperidine; (ii) standard DIC coupling; (iii) 
0.4 M Fmoc-AA and 1.2 M CDI in DMF, then, capping, then 20% piperidine; (iv) standard 
DIC coupling, then, capping, then 20% piperidine; (v) 0.5 M photocleavable linker, 0.5 M 
Et3N in DMF; (vi) 2% NH2NH2; (vii) 0.05 M BOP, 0.05 M 6-Cl-HOBt and 0.1 M DIEA in 
DMF; (viii) modified reagent K. 
 
Distefano’s group screened those C-terminal libraries to determine the peptide 
specificity of protein farnesyltransferase (PFTase). PFTase catalyzes the transfer of a 
farnesyl (C15) group of farnesyl diphosphate to the C-terminal Ca1a2X motif of a 
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peptide or protein (Figure 1.8). To determine the peptide substrate specificity of 
PFTase, each membrane was subjected to PFTase-catalyzed prenylation with an 
alkyne-containing FPP analogue followed by derivatization with biotin-azide via 
copper-catalyzed azide-alkyne cycloaddition (CuAAC). Those peptides that were 
prenylated by PFTase were conjugated to biotin at this step. The membrane was then 
subjected to an enzyme-linked assay involving streptavidin-alkaline phosphatase 
(SA-AP) and the chromogenic substrate 5-bromo-4-chloro-3-indolyl phosphate 
(BCIP). Spots containing prenylated peptides appear turquoise colored, whereas spots 
where the prenylation reaction was inefficient remain colorless (Figure 1.16). They 
screened the C-terminal libraries to study the specificity of R. norvegicus PFTase 
(rPFTase). They also investigated the interplay between peptides and isoprenoid 
substrates of varying length (C5, C10 and C15) and the specificity of PFTases from 
different organisms (R. norvegicus, S. cerevisiae and C. albicans).39,40 
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Figure 1.16 Screening and imaging strategy using CVIA (a substrate) and CVIL 
(nonsubstrate) as examples. Post-reaction colorization was accomplished by click reaction 
with biotin-azide followed by incubation with SP-AP. Colorization occurred upon the addition 
of BCIP.  
 
The limitation of the SPOT synthesis is the small library size, usually several 
hundred members per 10×15 cm2 membrane. This is a common problem for parallel 
synthesis. If OBOC method is adopted, it is routine to generate and screen a library of 
105-107 members. However, since all beads are mixed during screening, to determine 
the sequence of a positive bead (decoding), a tagging procedure should be used during 
the library synthesis. For example, Bradley and coworkers made an inverted tripeptide 
library to be screened by guanidinium-based tweezer receptor (Figure 1.17).41 In their 
synthetic scheme, 80% of the functional groups of a bead are used to make an 
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inverted peptide library and the remaining 20% are to incorporate a coding tag. After 
the C-terminal tripeptide library was generated, it was screened by binding to a 
solution of dansyl-labeled peptide tweezer receptor or dansyl-labeled peptoid tweezer 
receptor (Figure 1.18). Highly fluorescent beads were picked up and treated with 
100% TFA to expose N-terminal peptides whose sequences are the same as the 
C-terminal peptides of the same beads. The peptide sequences on those beads can then 
be sequenced by Edman degradation. 
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Figure 1.17 Synthesis of resin-bound peptides with free C-termini and post-screening 
treatment. Reagents and conditions: (a) standard SPPS; (b) HMPB, DIC, DMAP (80% of 
amine sites); (c) Fmoc-Ala, DIC, HOBt; (d) 20% piperidine; (e) split and mix Fmoc-SPPS; (f) 
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p-NO2C6H4OCO2CH2C6H4OCH2CO2Allyl; (g) Pd(PPh3)4, dimedone; (h) PyBOP, DIEA, 
DMAP; (i) 1% TFA / DCM; (j) MeOH; (k) screen linrary (l) treat positive beads with 100% 
TFA. 
 
(a)                              (b) 
 
Figure 1.18 Structure of (a) dansyl-labeled peptide tweezer receptor. (b) dansyl-labeled 
peptoid tweezer receptor. 
 
Saving a portion of the loading of a bead for tagging is a good way for later 
structural determination. However, if both the inverted peptides and the encoding 
peptides are randomly attached on the beads as in the above example, the encoding 
peptides could potentially interfere with library screening. To solve this problem, 
Lam’s group has developed a simple method to spatially segregate TenaGel beads into 
inner and outer layers.42,43 TentaGel resins are grafted coplymers consisting of 
polystyrene matrix on which polyethylene glycol is grafted. TentaGel beads are first 
soaked in water, drained and then quickly suspended in a mixture of dichloromethane 
and diethyl ether containing the derivatizing reagent. Because the inner phase of the 
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bead is still full of water which is not immiscible with the organic solvent, only 
peptides on the bead surface are exposed to and react with the reagent. The beads are 
then washed with DMF, and the inner remaining free N-terminal amino groups can 
react with a different reagent. Pei’s group adopted this method to make peptide 
libraries with free C-termini on the outer layer and N-termini in the inner layer 
(Figure 1.19).11,44 About 33% peptides of a bead were used for making a C-terminal 
peptide library. The majority of the loadings of a bead were used for coding. After 
making the cyclic structure, the ester bond can be selectively hydrolyzed in NaOH(aq) 
to generate a peptide with free C-terminus. An inverted peptide library containing five 
random residues was screened for binding to biotinylated PDZ domains. PDZ-bound 
resins were identified by subsequent treatment of SP-AP and BCIP buffer. The peptide 
sequences on those beads were sequenced by partial Edman degradation-mass 
spectrometry (PED/MS)5,45 because PED/MS sequencing is less time consuming than 
traditional Edman degradation sequencing. Pei’s group determined the binding 
specificity of the four PDZ domains of sodium-hydrogen exchanger regulatory 
factor-1 (NHERF1) and channel-interacting PDZ domain protein (CIPP),44 and later 
PDZ domains of the T-cell lymphoma invasion and metastasis 1 (Tiam1) and Tiam2 
proteins.11 They also used a similar strategy to determine the peptide specificity of 
BUZ domains of histone deacetylase 6 (HDAC6) and mutant ubiquitin processing 
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protease (Ubp-M) to see if these BUZ domains can bind to other peptide sequences 
other than Ub.46 In this work, they used HMPA instead of HMBA as the linker to 
make the ester bond. Because ether bond between the HMPA and the connected 
amino acid can be cleaved in acidic condition, ring cleavage and side-chain protecting 
group removal can be performed at the same time by TFA treatment. 
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Figure 1.19 Synthesis of spatially segregated and inverted peptide library. Reagents and 
conditions: (a) standard Fmoc-SPPS; (b) soak in water and then 0.33 eauiv. of 
Fmoc-Glu(δ-NHS)-OAll in CH2Cl2 / Et2O; (c) Boc-Gly-OH, HBTU; (d) 20% piperidine; (e) 
HMBA, HBTU; (f) TFA; (f) Fmoc-Arg(Pbf)-OH, HBTU; (h) Pd(PPh3)4; (i) 20% piperidine; (j) 
PyBOP, HOBt; (k) NaOH(aq); (l) TFA.  
 
Lam’s group used the same bilayer, peptide inversion strategy to discover 
specific peptide ligand against vancomycin.47 Vancomycin was labeled with biotin to 
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facilitate the identification of bound beads. XXXK(Ac)aa tripeptide libraries were 
screened first (a stands for d-Ala) (Figure 1.20). Later, more focused secondary 
libraries (YELK(XXX)aa, and XXXXaa) were designed and screened. A ligand with 
50-fold higher binding affinity to vancomycin than the native ligand Kaa was 
identified. 
 
 
Figure 1.20 Synthesis of spatially segregated and inverted peptide library.  
 
(c) Phage display 
As mentioned in part b of section 1.1, many types of phages have been adapted 
for phage display. If phage display is used to screen C-terminal peptide libraries, one 
must choose a phage and a coat protein of it that has C-terminus exposed so that a 
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peptide library can be appended to its C-terminus. λ phage is a good choice (Figure 
1.21).48 The carboxyl terminus of the D-capsid protein does not involve in head 
formation49 so random peptides can be displayed on the surface of λ phage by fusion 
to the carboxyl terminus of D proteins. After the DNA library of λ display vector is 
prepared, it can be incorporated into phage particles by in vitro packaging. Those λ 
phages can be propagated by infecting the host bacteria cells. After the phage multiply, 
their progeny will display the corresponding protein sequence on their surface along 
with the head proteins. 
  
 
Figure 1.21 A model of phage λ, indicating protein-protein interactions. Proteins in bold 
font have known structures. Numbers indicate the number of protein copies in the particle.48 
 
Dente and coworkers used λ phage to display nonapeptides of random sequences 
with free C-termini.9 In their system, about 95% of the total D protein is chimeric and 
the remaining 5% is synthesized by a second wild-type gene in the phage vector. 
Seven PDZ domains of the human INADL protein were expressed, immobilized on 
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beads and screened to determine their binding specificities. Different consensus 
binding sequences were defined for each hINADL PDZ domain. Later they used a 
similar λ phage strategy to determine the five PDZ domains in the protein tyrosine 
phosphatase PTP-BL.50 In this work they not only screen and find the specificity of 
each separate PDZ domain but also investigate the binding preferences of several 
combinations of PDZ domains. Interestingly while a protein segment spanning the last 
two PDZ domains of PTP-BL (PDZ4+5) did not reveal an altered binding preference 
relative to PDZ4, the combination of the first two PDZ domains (PDZ1+2) displayed 
a more stringent selectivity than PDZ2 alone. This demonstrates that there is an 
allosteric interaction between PDZ1 and PDZ2, and the ligand selectivity of PDZ2 
can be modulated by PDZ1. 
T7 phage is also a good choice for C-terminal peptide display. The procedure of 
T7 phage display is similar to λ phage display except the peptide-coding sequence to 
be displayed is cloned into the phage DNA to make a translational fusion to the head 
protein, gp10, of the phage (Figure 1.22).51 Since there are 415 of head proteins per 
phage, a large number of copies of peptide can also be expressed from each phage, 
enhancing binding. Bredesen and coworkers used T7 phage display to determine the 
specificity of six PDZ domains from the synaptic proteins PSD-95 and SAP97.52 
Later Spaller and coworkers also used T7 display method to determine the specificity 
 35
of the 10th PDZ domain of the multi-PDZ domain protein 1 (MUPP1) and the 3rd 
PDZ domain of PSD-95.53 
 
  
Figure 1.22 The structure of bacteriophage T7.51 
 
Ruoslahti and coworkers used T7 phage display to identified peptides that can 
bind to human prostate cancer cells PPC-1.54 The cancer cells were incubated with the 
phage libraries, washed, and then lysed to release the phages. The selected phages 
were determined to display a consensus sequence R/K-X-X-R/K. The strict 
requirement for a basic C-terminal amino acid is termed C-end rule. The bound phage 
could also be internalized into the cells at 37 oC. Affinity chromatography and 
immunostaining identified cell receptor NRP-1 as the target responsible for the C-end 
rule. NRP-1 is a known mediator of vascular permeability.14,15 Intravenously injected 
positive phages penetrated into tissue parenchyma, but not negative control, indicates 
that the C-end rule peptides can cause vascular leakage and tissue penetration. 
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M13 phage is another common phage used for phage display. In contrast to some 
phages that lyse the cell to release themselves such as λ, T4 and T7 phages, M13 
phage is secreted through the membrane of bactreria. Of the five coat proteins of the 
M13 phage, pIII and pVIII are the most commonly used coat proteins to make 
translational fusion for phage display (Fidure 1.23). In the M13 phage display 
technique, after a DNA library of M13 display vector is prepared, they are 
transformed into E. coli cells. However, the M13 vector alone does not encode all the 
necessary proteins to make progeny phage. Then the cells are infected with a helper 
phage which supplies normal head protein. So in the assembled phage, the fusion 
proteins are usually mixed with the wild-type protein in the head.  
 
 
Figure 1.23 Schematic representation of the filamentous bacteriophage M13. 
 
Unfortunately there is a problem in our case: in the natural assembly of M13 
phage, it is the N-terminus of pIII and pVIII that is solvent-exposed whereas the 
carboxyl terminus is buried in the particle.55,56 So in M13 phage display, the random 
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peptide sequence is usually inserted between the signal sequence required for 
secretion of the head protein and the N-terminus of the mature protein where it will be 
displayed on the surface of the phage. However, Sidhu and coworkers found that 
although the pVIII C-terminus is buried in the particle core, C-terminal fusions can 
still be displayed. They screened a heptapeptide library to investigate the binding 
specificities of PDZ domains 2 and 3 of MAGI 3, a membrane-associated guanylate 
kinase.57 In their M13 phage system, there is an intervening linker of 13 residues 
between the C-terminus of pVIII and the random peptide to make sure the C-terminal 
peptides can be accessible for interaction to the target protein. They also used this 
methodology to identify ligands for the Erbin PDZ domain.58 Later they improved 
their system by screening libraries of mutated pVIII protein (plus a ten residue linker) 
for better C-terminal peptide display. Interestingly, the selected pVIII mutants 
containing mutations spanning near the N-terminus to near the C-terminus. Their 
optimal pVIII mutants showed C-terminal display more than 100-fold relative to the 
wild-type.59 They used the optimized methodology to determine the peptide 
specificity of about half of the PDZ domains known to exist in the human and C. 
elegans proteomes.60 They also screened the M13 phage libraries of all human and 
viral C-terminal peptides against nine PDZ domains of human Densin-180, Erbin, 
Scribble, and Disks large homolog1.61 
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Yin’s group used a different strategy to display protein libraries connecting to 
pIII of M13 phage. pIII, like pVIII, has its N-terminus exposed to solvents. One clever 
way to use pIII to display a C-terminal library is to link the peptide library to pIII in 
the periplasm of the cell after it has been secreted instead of translationally fusing the 
library to pIII. In their system, pIII and the protein to be displayed are expressed from 
different genes on the M13 display vector and both have a signal sequence. A Jun 
peptide sequence is placed before the N-terminus of pIII, and a Fos peptide sequence 
is placed before the N-terminus of the protein library. The Jun-pIII and the 
Fos-protein will be secreted separately into the periplasm and form a heterodimer due 
to the binding of Jun-Fos coiled coil and two disulfide bonds between Jun-Fos. In this 
way, phage assembly anchors the Jun-Fos dimer on the phage surface and the 
displayed protein is connected to the dimer with an exposed C-terminus (Figure 1.24). 
Because the cross-linking of the two proteins occurs before the phage leaves the cell, 
the vector DNA that encodes both of them is packaged in the phage head. 
 
   Figure 1.24 Phage display of Ub with free C-terminus.62  
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Yin’s group is interested in the ubiquitin modification pathway. Ub and UBLs are 
activated by specific E1 enzymes (Figure 1.10). It was reported that the C-terminal 
peptide of Ub plays a key role in recognition of E1 by crystal structure.63 A Ub library 
with random sequences from residue 71 to 75 (Ub has 76 residues) was screened to 
determine the specificity of 2 E1 enzymes (Ube1 and Uba6).64 The E1 protein was 
immobilized on a solid support. Selection of phage-displayed Ub library is based on 
the formation of a Ub-E1 conjugate. The enriched phage particles can be eluted with 
DTT treatment by cleaving the thioester conjugate (Figure 1.25).64 Later they used a 
similar strategy to screen a C-terminal library of Nedd8, a ubiquitin-like protein, to 
profile the specificity Nedd8 activating E1 enzyme (NAE).65 They also made a mutant 
E1 (termed A1) which cannot activate wild-type Ub and screened a Ub library against 
the A1 by the above screening strategy to find Ub mutants which can be recognized 
by A1. Subsequent optimization resulted in an orthogonal Ub-E1 system in which the 
engineered Ub can be transferred to A1 but there is no cross-activities with wild-type 
Ub and E1.62 
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Figure 1.25 Phage selection of the Ub library.64 
 
1.3 Summary 
A variety of methods to synthesize and screen peptides have been reviewed in 
this chapter with the focus on peptide libraries with free C-termini. Each method has 
its own advantages and disadvantages. The principle of SPOT synthesis is simple. 
Different peptides are displayed on different locations of a membrane. The positions 
of the spots on the membrane tell the corresponding peptide sequences. This makes 
the sequence determination easier whereas the beads are mixed in OBOC method 
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making a tagging procedure needed. However, the library size of SPOT synthesis is 
really small compared to OBOC method or phage display making the sampling of all 
chemical space difficult. Phage particles can display protein on its coat protein. Hence, 
protein libraries can be screened by phage display whereas in solid-phase peptide 
synthesis, a peptide sequence within 30 residues is usually synthesized linearly. Phage 
libraries can also be injected into animals to do in vivo screening.  
Because the solid support of SPOT synthesis and OBOC method is inert, 
chemical reactions can be performed easily on it whereas proteins tend to denature in 
organic solvent making phages lose activity. Unnatural amino acids (UAAs) can be 
easily incorporated into peptides by SPPS but Nature encodes 20 amino acids only. 
Although enzymatic transformation or genetic code expansion technique are able to 
diversify peptides made by cellular machinery, the diversity of the resulting peptides 
still cannot compete with chemical synthesis. A summary of the advantages and 
disadvantages of those methods is shown below (Table 1.1).  
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Category Advantage Disadvantage 
SPOT synthesis Easy to decode sequences 
Easy to incorporate UAAs 
Easy to do chemical derivatization
Small library size (~103) 
OBOC Big library size (~10
6) 
Easy to incorporate UAAs 
Easy to do chemical derivatization
Tagging is needed to decode 
sequences 
Cannot make protein libraries 
Phage display Big library size (~10
9) 
Can display peptide or protein 
libraries  
In vivo screening is possible 
Difficult to incorporate UAAs 
Unstable in organic solvent 
Table 1.1 A comparison of SPOT synthesis, one-bead-one-compound and phage display 
methods for synthesis and screen peptide libraries. 
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Chapter 2. Isoprenoid Analogues Used in the Study of Protein Prenylation 
 
2.1 Introduction to prenyltransferases 
After protein is synthesized, the structure can be modified by other enzymes. For 
example, a protein can be cleaved by a protease, phosphorylated by a kinase or 
lipidated by a prenyltransferase. This process is called post-translational modification. 
The purpose of post-translational modification is to switch on (or switch off) an 
enzyme’s activity, to locate the protein to certain region in the cell or to change the 
binding affinity to other proteins. Protein prenylation with isoprenoids has been the 
focus of numerous studies since its discovery in the early 1990’s because of its 
connection to cancer.66 Members of the Ras family proteins are normally prenylated 
and mutated forms of Ras, especially K-Ras, are involved in as many as 30% of all 
human cancers.67 Members of the protein prenyltransferase class of enzymes include 
protein farnesyltransferase (PFTase) and geranylgeranyltransferase I (GGTase I). 
These prenyltransferase enzymes are heterodimers. The α-subunit of PFTase and 
GGTase-I are the same but the β-subunit of these proteins are only about 25% 
sequence identical68 (Figure 2.1).  
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(a)                               (b) 
 
Figure 2.1 Alignment of the crystal structures of PFTase (brown, PDB 2BED) and 
GGTase-I (cyan, PDB 1N4P). (a) α-subunit. (b) β-subunit. Structures were overlaid using 
“Compare Structures” function on the RCSB website. 
 
PFTase and GGTase-I catalyze the transfer of farnesyl (C15) and geranylgeranyl 
(C20) groups respectively, from the corresponding diphosphates. In the resulting 
alkylated protein, the isoprenoid group is linked to a cysteine residue within the 
C-terminal amino acid sequence referred to as a Ca1a2X motif where C is a cysteine, 
a1 and a2 are usually aliphatic amino acids and X is the major determinant for 
modification by either PFTase or GGTase I (Figure 2.2).19,20 It has been reported that 
farnesylation by PFTase occurs when X is alanine, serine, methionine or glutamine, 
while geranylgeranylation by GGTase I occurs when X is leucine or phenylalanine. 
Additional proteins are di-geranylgeranylated at their C-termini when they contain 
 45
sequences including CC and CXC; these latter sequences are prenylated by protein 
geranylgeranyltransferase type II (GGTase-II). GGTase-II, also called RabGGTase, 
differs both structurally and functionally from the canonical PFTase and GGTase-I 
because it recognizes more extensive elements from its cognate protein substrates, 
Rab proteins.69  Once prenylated, the resulting proteins move to the endoplasmic 
reticulum where they are further processed by proteases that remove the a1a2X 
tripeptide and methylated by a SAM-dependent methyltransferase to produce proteins 
with a C-terminal methyl ester.70  
 
 
Figure 2.2 C-terminal prenylation and subsequent proteolysis and methylation. The 
prenyl group could be farnesyl group (C15) (shown in this figure) or geranylgeranyl group 
(C20). 
 
Protein prenylation is not only common in mammals71,72 but is also a ubiquitous 
post-translational modification in all eukaryotes. For example, prenylated Ras is a 
more potent in vitro activator of S. cerevisiae adenylyl cyclase than is the 
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non-prenylated form.73 It has also been found that prenylation of signal transduction 
proteins is essential for viability of C. albicans which is an opportunistic fungal 
pathogen.74 Other groups have identified prenylated proteins and confirmed their 
significance in P. falciparum which is the causative agent for malarial disease.75 A 
vast array of prenylation inhibitors have been developed to combat numerous illnesses 
caused by cancers, protozoan pathogens, and fungal infections.76-79 Recently, interest 
in prenylation has expanded to include biotechnology applications since 
prenyltransferases can be used to enzymatically incorporate non-natural functional 
groups into protein substrates.80-82 The resulting modified polypeptides can be further 
transformed via bio-orthogonal reactions to produce a variety of useful species 
including PEGylated proteins,83 protein multimers84 and protein-DNA conjugates.85  
 
2.2 Fluorescent analogues 
Since the native isoprenoid substrates of prenylation (FPP and GGPP) do not 
have special spectroscopic properties, this makes the monitoring the localization of 
intracellular proteins and biochemical characterizations difficult. The fluorescent 
derivatives (Figure 2.3) can be used to label proteins in vitro or in live cells and have 
the application for studying the interaction and subcellular localization of prenylated 
proteins. 
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Figure 2.3 Fluorescent analogues of FPP or GGPP. 
 
The first way to derivatize FPP or GGPP into fluorescent molecules is to extend 
double bond conjugation to make FPP analogue (ΔΔFPP, 2-1 a) and GGPP analogue 
(ΔΔGGPP, 2-1 b).86,87 The alcohol of 2-1 b (ΔΔGGOH) showed blue fluorescence in 
methanol, with λex = 310 nm and λem = 410 nm but the fluorescence intensity at 410 
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nm was largely quenched in aqueous solution. Side-chain prenylation of N-acetylated 
Cys methyl ester with 2-1 b (AcCys(ΔΔGG)Me) showed λex = 360 nm and λex = 460 
nm in Tris buffer demonstrating the environmental sensitivity of the ΔΔGG 
fluorophore. 2-1 b is a substrate for yeast GGTase-I with a KM value of 0.33 μM (3.45 
μM for GGPP) but the prenyl-transfer efficiency was lower than that of GGPP. The 
dissociating constant (KD) of AcCys(ΔΔGG)Me to RhoGDI, which forms a complex 
with geranylgeranylated Rho protein, is 15.1 μM (2.45 μM for AcCys(GG)Me) 
indicating that the more rigid ΔΔGG had lower affinity. The alcohol of 2-1 a (ΔΔFOH) 
displayed blue fluorescence in methanol, with λex = 360 nm and λem = 465 nm but 
again the fluorescence is quenched with increasing content of water. Unfortunately 
2-1 a is not a substrate for yeast PFTase but a potent competitive inhibitor (Table 1). 
All of the subsequent fluorescent analogues are derived from appending an extra 
fluorophore onto the isoprenyl chain. The first two examples of such analogues are 
N-methylanthranilate-labeled FPP analogue (mGPP, 2-2 a) and GGPP analogue 
(mFPP, 2-2 b).88,89 Both compounds had λex at 340 nm and λem at 435 nm and both 
compounds are substrates for GGTase-II with 2-2 b binding better than 2-2 a because 
2-2 b is structurally more similar to GGPP. 
The first advantage of appending a fluorophore onto the isoprenoid chain is to 
determine binding affinity and kinetics. Previous attempts to determine these 
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properties depend on changes in the intrinsic tryptophan fluorescence in the active site 
but in some cases the intensity changes are small. If an extra fluorophore is attached 
to the isoprenoid chain and binding of the fluorescent derivatives to the enzymes 
results in significant fluorescence changes, binding affinity can be measured by 
fluorescence titration. Then the binding affinity of non-fluorescent substrates can be 
determined by competitive fluorescence titration. In fact, the binding constants of 2-2 
a and 2-2 b for GGTase-II were determined in this way. The transient kinetics of 2-2 a, 
2-2 b, FPP and GGPP interaction with GGTase-II were determined similarly but the 
signal was from fluorescence resonance energy trabsfer between tryptophan and 
N-methylanthranilate. 
Although compound 2-2 a and 2-2 b have applicability on enzymatic assays, the 
ester linkage in the structure might be cleaved by nonspecific esterase in cellular 
experiments. A more stable anthranylate derivative with amine linkage (2-3) should 
overcome this problem. Compound 2-3 has λem at 435 nm. Incubation of cells with 
compound 2-3 led to the accumulation of non-prenylated Ras, which can be prevented 
by FPP, indicating compound 2-3 is likely a competitive inhibitor with respect to 
FPP.90 The alcohol version of compound 2-3 is toxic to RPMI-8402 human leukemia 
cells with IC50 of ~10 nM. The fluorescent analogues 2-4 and its alcohol version could 
also be visualized within cells by fluorescent microscopy but their other properties 
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were not further demonstrated. 
Compound 2-5 was originally designed to study Undecaprenyl pyrophosphate 
synthesase (UPPs) which produces C55 undecaprenyl pyrophosphate pyrophosphate 
(UPP) via consecutive condensation reactions of eight IPP with an FPP.91 In aqueous 
solution, compound 2-5 displays λex = 336 nm and λem = 460 nm. Due to the 
electron-withdrawing ability of CF3, the lowest unoccupied molecular orbital (LUMO) 
is lowered compared to the CH3 counterpart resulting in red shift of both λex and λem. 
Compound 2-5 is not only an inhibitor for UPPs but also a slow substrate for UPPs. 
The KM of compound 2-5 is consistent with its Ki and is also similar to the KM of FPP 
but the reaction is 125-fold slower compared to the reaction using FPP. Because UPPs 
can quench the fluorescence of compound 2-5, the binding process of UPPs was 
monitored by stopped-flow spectrofluorimeter to calculate transient kinetics. 
Distefano’s lab also found that compound 2-5 is a slow substrate for PFTase because 
of structural bulkiness of compound 2-5 relative to FPP. The molecular volume of 
compound 2-5 is about 25% bigger than FPP. kcat/KM of compound 2-5 is about 380 
times lower than FPP. However, it was shown that if the active site of PFTase is 
expanded by mutating Tyr at 205 to Ala, the mutant enzyme can use compound 2-5 
much more efficiently (kcat/KM increases about 300 times compared to wild-type 
enzyme) (Table 1). 
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In the design of fluorescent isoprenoid analogues, the fluorophore should be 
small to mimic the natural substrate but the fluorescent intensity should also be high 
to make the measurement easy. 7-nitro-benzo[1,2,5]oxadiazol-4-ylamino (NBD) is 
one of the fluorophore that fulfills the compensation between structure minimum and 
fluorescent intensity maximum. FPP analogues (NBD-GPP, 2-6 a) and GGPP 
analogues (NBD-FPP, 2-6 b) have λex = 487 nm and λem = 550 nm.92 Addition of 
excess PFTase, GGTase-I and GGTase-II to a solution of 2-6 a or 2-6 b resulted in 
large fluorescent changes. This allowed the binding constant to be determined by 
fluorescence titration (Table 1).  
The second advantage of appending a fluorophore onto the isoprenoid chain is 
visualizing prenylated proteins easily if that isoprenoid analogue is a substrate. In the 
in vitro prenylation assay, prenylated protein can be resolved on SDS-PAGE and 
fluorescence intensity be quantified as exemplified with 2-2 a, 2-2 b, 2-6 a and 2-6 b. 
If the sensitivity of the assay is high enough, steady-state kinetics can be measured as 
in the case of 2-6 a and 2-6 b (Table 1). In the cell labeling, in vivo conjugation can 
be imaged if the isoprenoid analogue is stable. Transiently expressed EYFP-Ki-Ras 
and ECFP-RabGDI in COS-7 cells in the presence of 2-6 a or 2-6 b can be seen on 
subsequent SDS-PAGE analysis. Intracellular distribution of compound 2-6 b in 
human epidermal carcinoma A431 cells was also seen under fluorescence 
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microscope.92  
BODIPY-labeled derivatives 2-7 a and 2-7 b displayed large fluorescence 
changes upon binding to protein prenyltransferase, which allowed for the 
determination of their affinities using fluorescence titration experiments.93 The results 
showed that 2-7 a, 2-7 b, and FPP have similar affinities for PFTase and 2-7 a and 
GGPP have similar affinities for GGTase-I. However, GGTase-II displayed an affinity 
for 2-7 a approximately an order of magnitude lower compared to FPP. Unfortunately 
among the three enzymes, only GGTase-II can utilize 2-7 a to prenylate its protein 
substrates. PFTase and GGTase-I could not use 2-7 a as a substrate. Time-resolved 
changes in polarization of BODIPY fluorophore was used to determine KM for 
GGTase-II-mediated transfer of 2-7 a onto Rab 7, suggesting 2-7 a is an efficient 
substrate for GGTase-II. Compound 2-7 a was also used to monitor its localization in 
baby hamster kidney (BHK) cells and in zebrafish. 
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Compound 
Fluorescence 
property 
Substrate? 
Inhibitor? 
Kinetic constants 
FPP ND S 
yPFTase: Km = 27 μM 
(DsGCVLS)87 
mPFTase: Km = 46 nM94, 28 
nM95 or 1.5 uM96 (DsGCVLS) 
mGGTase-II: Kd = 60 nM89 
GGPP ND S 
yGGTase-I: KM = 3.45 μM86 
(DsGCVLL) 
mGGTase-I: Kd = 0.25 nM92 
mGGTase-II: Kd = 8 nM89 
2-1 a 
λex = 360 nm, 
λrm = 465 nm 
in methanol 
I 
yPFTase: Ki = 8.8 μM87 
2-1 b 
λex = 310 nm, 
λrm = 410 nm 
in methanol 
S 
yGGTase-I: KM = 0.33 μM86 
(DsGCVLL) 
2-2 a S mGGTase-II: Kd = 330 nM
89 
2-2 b 
λex = 340 nm 
λrm = 435 nm S mGGTase-II: Kd = 49 nM
89 
2-3 
λex = ~340 nm 
λrm = 422 nm 
I 
mPFTase: IC50 = ~ 50 nM90 
2-5 
λex = 336 nm 
λrm = 460 nm 
S 
mPFTase (WT):   
KM =1.4 μM, kcat =1.3×10-3 s-1 
(GfP-CVIA) a 
mPFTase (Y205A):   
KM =0.12 μM, kcat =0.035 s-1 
(GfP-CVIA) a 
2-6 a S 
mPFTase: Kd = 1.6 nM 
KM = 0.5 μM, kcat = 0.09 s-1 
(K-Ras)92 
2-6 b 
λex = 487 nm 
λrm = 550 nm 
S 
mGGTase-I: Kd = 6 nM 
KM = 0.03 μM, kcat = 0.08 s-1 
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(RhoA)92 
mGGTase-II: Kd = 328 nM 
KM = 4.7 μM, kcat = 0.04 s-1 
(Rab7)92 
2-7 a 
S only for 
GGTase-II 
mPFTase: Kd = 1.1 nM 
mGGTase-I: Kd = 0.23 nM 
mGGTase-II: Kd = 245 nM; KM = 
0.2 μM (Rab7)93 
2-7 b 
λex = 490 nm 
λrm = 505 nm 
I mPFTase: Kd = 4.9 nM 
a Dozier, J. K.; Khatwani, S. L.; Wollack, J.; Wang, Y.; Schmidt-Dannert, C.; Distefano, M. D. 
Bioconjugate Chem. 2014, DOI: bc-2014-00240p.R1 
Table 2.1. Summary of fluorescent isoprenoid analogues 
 
2.3 Probes to detect prenylome 
Protein prenylation is a widespread phenomenon in eukaryotic cells that affects 
many important signaling molecules. However, the total number of prenylated 
proteins which are referred to prenylome is still not clear. Only a fraction of predicted 
prenylated proteins were experimentally confirmed, leaving the true size of the 
eukaryotic prenylome unknown. Prenylated proteins have been traditionally detected 
by metabolic labeling with radioactive substrates such as [3H]FPP and [3H]GGPP. 
However, this method suffers from some disadvantages such as low sensitivity and 
long exposure times for detection (weeks to months). To address these limitations, 
chemical probes of protein prenylation have been developed to improve the detection 
of prenylated proteins (Figure 2.4). 
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Figure 2.4 Probes for studying prenylome. 
 
In order to detect prenylated proteins in cells, there must be a handle on the 
isoprenyl chain which allows researchers to observe those proteins or to capture them. 
Biotinylated derivatives (B-GPP, 2-8 b) allowed the prenylated proteins to be enriched 
by streptavidin beads. The enriched prenylome can subsequently be analyzed by 
Western blot or MS.97 The affinity of compound 2-8 b for the PFTase, GGTase-I and 
GGTase-II is reduced compared to the native substrates but is comparable to that of 
other derivatized isopreniod analogues. Unfortunately, compound 2-8 b is only a 
substrate for GGTase-II. No or only residual transfer activity could be detected for 
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PFTase and GGTase-I, respectively. Mutants of the PFTase (W102T_Y154T or 
W102T_Y154T_Y205T) and GGTase-I (F52Y_F53Y_Y126T) with expanded active 
sites were found to use compound 2-8 b as a substrate. There are two disadvantages of 
using compound 2-8 b as a probe to detect prenylome. First, if PFTase-prenylome or 
GGTase-I-prenylome is the goal, cells must be transfected to express mutant enzymes. 
This adds an extra complication. Second, it is known from crystallography that in the 
active site a peptide substrate and an isoprenoid substrate physically contact each 
other in some part98 so the structure of the isoprenoid can influence the peptide 
specificity. The identified prenylome may not be the native prenylome if the 
isopreniod analogues are structurally very different from FPP or GGPP. Although 
compound 2-8 b was demonstrated to be delivered to their cognate substrates 
faithfully and orthogonally by the engineered prenyltransferase, structural 
perturbation is always a concern. Biotinylated derivatives with shortened chain length 
(B-DMAPP, 2-8 a) was again transferred only by GGTase-II and was transferred less 
efficiently than compound 2-8 b.93 This suggested that shortening of the isoprenoid 
chain resulted in reduction of the affinity for the enzyme. 
A solution for the above mentioned problems is to use an isoprenoid analogue 
with small functional handle. After prenylation, a capture/labeling reagent was 
attached via a bioorthogonal chemical ligation technique. The choice of the ligation 
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reaction depends on the downstream application with the common ones being the 
‘click’ reaction and Staudinger reaction. The advantage of this strategy is that different 
types of reagents can be ligated with one kind of isoprenoid analogue. A number of 
such reagents includes affinity labels (e.g., biotin, FLAG, etc.), reporter dyes and 
oligonucleotide tags. Isoprenoids of this kind include compound 2-9 a, 2-9 b, 2-10 a, 
2-10 b, 2-11a and 2-11 b. They are all substrates of PFTase. 
Growth of COS cells in the presence of compound 2-9 a or its alcohol version 
resulted in incorporation of these azide-containing analogues into proteins. 
Chemoselective derivatization of prenylated proteins by a Staudinger reaction was 
done by using a biotinylated phosphine capture reagent.99 The resulting protein 
conjugates can be specifically detected or affinity purified by streptavidin-linked 
horseradish peroxidase or agarose beads. Subsequent MS analysis identified a number 
of farnesylated proteins including those with potentially novel farnesylation motifs. It 
was reported that the azide of compound 2-9 a can isomerize between C-12 and 
C-10.100 Use of compound 2-9 b should overcome this problem. 
The rapid rate of the Cu(I)-catalyzed click reaction has made it the method of 
choice for many proteomic profiling protocols other than Staudinger reaction. 
However, background labeling occurs in the click reaction when the alkyne reagent is 
present in excess.101,102 Significantly lower levels of non-specific reaction occur when 
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the azide partner is employed in high concentration. In fact, Distefano’s group 
compared the labeling of prenylated proteins with TAMRA fluorophore in HeLa cells 
when incubating with compound 2-10 a or alcohol version of 2-9 a. SDS-PAGE and 
then in-gel fluorescence analysis showed that using compound 2-10 a reduced 
background labeling.101 2-D gel electrophoresis of labeled proteins from HeLa cells 
grown in the presence of alcohol version of  2-10 a or 2-10 b followed by MS 
analysis allowed several labeled proteins to be identified. 
Hang and coworkers have compared the labeling signals and patterns of 2-9 a, 
2-10 a, 2-11 a and 2-12 a.102 Jurkat cells were treated with alcohol version of 2-9 a, 
2-10 a, 2-11 a and 2-12 a. Cell lysates were conjugated via CuAAC to 
azido-rhodamine or alkynyl-rhodamine. Lysates were separsated by SDS-PAGE and 
scanned for fluorescence. Robust signal over background was obtained using 2-10 a, 
2-11 a and 2-12 a compared to 2-9 a. This is consistent with other reports.101 Labeling 
was stronger with 2-10 a and 2-11 b than 2-9 a and 2-11 a. In his research, 2-10 a was 
chosen for subsequent experiments because 2-10 a was claimed to be readily 
synthesized and was stable compared to other alkyne-derivatized probes.102,103 
Antibodies are useful both in the routine detection and immunoprecipitation of 
proteins with other post-translational modifications. However, it was reported that 
antibodies produced to detect farnesylated proteins showed cross-reaction with 
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geranylgeranylated proteins or others.104-106 An alternative approach to detect 
prenylome is to produce antibodies against proteins modified with unnatural farnesyl 
analogues. In this way, it is less likely that the raised antibodies will cross-react with 
other proteins. Since compound 2-12 (AGPP) is also an effective alternative substrate 
for PFTase, Spielman and coworkers have produced antibodies specific for the 
anilinogeranyl moiety.107 The alcohol version of compound 2-12 was incorporated 
into cellular proteins in a PFTase dependent manner. In a subsequent report, 2-D 
electrophoresis and Western blot with these antibodies revealed farnesylated proteome 
in leukemia cells.108 
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Chapter 3: Solid-Phase Synthesis of C-terminal Peptide Libraries 
 
3.1 Introduction 
Early investigations of Ca1a2X substrate preferences of prenyltransferases 
involved mutations of the C-terminal sequences of Ras proteins. Individual 
purified proteins were assayed using [3H]-FPP or [3H]GGPP as the isoprenoid 
substrate.109 This method is inconvenient and labor-intensive. Subsequently, a 
fluorescence assay was developed to study peptide specificity of PFTase and 
GGTase-I110,111. That involves the preparation of dansylated Ca1a2X-box 
containing peptides, and measurement of dansyl-group fluorescence that increases 
upon prenylation.112 However, this method still requires the synthesis, purification 
and analysis of individual peptides which is a time-consuming process. 
Combinatorial approaches that use one-bead-one-compound libraries or peptide 
arrays provide possible strategies for increasing the number of sequences that can 
be examined. However, studies of protein prenylation present a number of 
challenges to implementing such methods. First, prenylation is a post-translational 
modification that occurs at the C-terminus of a protein. Since solid phase peptide 
synthesis is typically performed from the C- to N-terminus, more complex 
synthetic procedures are required to prepare libraries with free C-termini. Next, 
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prenyltransferases are large multimeric enzymes (~80 kDa or larger) whose size 
reduces their ability to penetrate into the resins typically employed for solid phase 
synthesis; the enzymes responsible for the subsequent processing of prenylated 
proteins are membrane-bound presenting additional challenges. Finally, 
isoprenoids are not intrinsically chromogenic and are sensitive to acidic conditions 
and electrophiles; those features make the enzymatic addition to peptides on resin 
difficult to monitor and the subsequent cleavage and sequence analysis more 
complex. In this chapter, we describe the synthesis of a library of peptides 
containing free C-termini on cellulose membranes. The resulting library was then 
used to probe the specificity of protein farnesyltransferase from S. cerevisiae 
(yPFTase). 
 
3.2 Synthesis of a peptide library with free C-termini and its screening 
against yPFTase 
Our approach for the preparation of peptide libraries with free C-termini 
(Figure 3.1) is based on the pioneering work of Kania, Zuckermann and Marlowe31 
and key improvements contributed by others.32,46  A four residue linker BBLL 
was initially added on to amine-functionalized solid surfaces. The resulting 
peptide was then coupled to the　γ-carboxyl group of Fmoc-Glu-ODmab; this 
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resulted in the installation of an orthogonally (Dmab) protected carboxylate that 
could be used for subsequent on-resin cyclization. Fmoc removal and coupling of 
an HMPA linker followed by ester bond formation produced a depsipeptide 
containing an acid-labile ester linkage. Seven residues were then sequentially 
added ending with a linker to permit cleavage of the final product from the resin at 
the end of the synthesis. After Dmab removal from the internal Glu, the resulting 
free amino- and carboxyl-groups were coupled to yield a cyclic peptide on resin; 
treatment with modified Reagent K caused cleavage of the internal ester linkage 
and afforded the desired linear peptide with a free C-terminus.  
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Figure 3.1 Synthesis of C-terminal peptides. Reagents and conditions: (i) standard DIC 
coupling of Fmoc-Aa (2×), then capping, then 20% piperidine, then BPB staining; (ii) 
standard DIC coupling of HMPA (2×); (iii) 0.5 M Fmoc-Aa and 0.5 M 6-Cl-HOBt in 
DMF/CH2Cl2, 0.5 M DIC in CH2Cl2, 0.2 M DMAP in CH2Cl2 (6-8×), then capping, then 20% 
piperidine, then BPB staining; (iv) standard DIC coupling of Fmoc-Aa (2×), then capping, 
then 20% piperidine, then BPB staining; (v) 0.5 M photolysis linker, 0.5 M Et3N in DMF 
(3-4×); (vi) 2% hydrazine; (vii) 0.05 M BOP, 0.05 M 6-Cl-HOBt and 0.1 M DIEA in DMF 
(2×); (viii) modified reagent K. PL represents a cleavable linker so that peptides can be 
cleaved from resin and analyzed by MS. B represents β-alanine. 
 
Initially, we planed to use Met as the linker in the PL position (Figure 3.1) 
and cleave the products after enzymatic prenylation from the resin using CNBr for 
subsequent analysis; previous reports suggested that prenylated cysteine was stable 
to CNBr. However, we found that after chemical farnesylation of the resin-bound 
peptide, treatment with CNBr resulted in significant amounts of prenyl group 
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cleavage. Additionally, CNBr cleavage suffers from slow kinetics and results in 
the formation of side products observed via MS (Figure 3.2).  
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Figure 3.2 MALDI analysis of peptide prepared using Met as the linker. The resin was treated 
with 100 mg/mL CNBr in 70% TFA overnight followed by solvent removal in vacuo. The 
peptide (RGCVLS) was re-dissolved in CH3CN/H2O (v/v = 5/95) with 0.1% TFA for 
subsequent MS analysis. 
 
To circumvent this problem, we initially examined the use of the 
photocleavable linker shown in Figure 3.3a. Incorporation of that structure into a 
peptide prepared via the route outlined in Figure 3.1 followed by chemical 
farnesylation and photocleavage produced the desired free peptide. However, 
analysis of that material was complicated due to the fragmentation of the nitroso 
ketone moiety that remained linked to the final peptide113 (Figure 3.4); while not 
problematic in the case of a single peptide, it could significantly complicate 
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matters in the context of library analysis.  
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Figure 3.3 Photocleavable linkers used for peptide synthesis in this study. 
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Figure 3.4 MALDI analysis of peptide prepared using first generation photocleavable linker 
(structure shown in Figure 3.3a). The resin was treated with UV light (365 nm) in 
CH3CN/H2O (v/v = 5/95) followed by washing with CH3CN and MeOH. The combined 
solvents were removed in vacuo and the resulting peptides (PL-RGCVLS) were re-dissolved 
in CH3CN/H2O (v/v = 5/95) with 0.1% TFA for subsequent MS analysis. 
 
Accordingly, a new photocleavablelinker, shown in Figure 3.3b, was designed 
and prepared (see Scheme S3.1). The resulting residue was incorporated into 
Loss of 
O 
Loss of 
O, N 
Loss of O, O, N 
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peptides as “PL” using the strategy outlined in Figure 3.1. After chemical 
farnesylation, photolysis of the resin resulted in clean formation of the desired 
peptide lacking the nitroso ketone substructure (which remained resin bound) 
(Fugure 3.5). 
With a workable strategy for the synthesis and analysis of relevant C-terminal 
peptides in hand, we next began to examine the enzymatic prenylation of these 
molecules. Unfortunately, treatment of TentaGel beads terminating in the sequence 
CVIA with PFTase and FPP for prolonged reaction time did not result in the 
formation of any detectable farnesylated product by MS after photocleavage; 
experiments employing a more hydrophilic PEGA resin as the solid support for 
synthesis gave similar negative results. Interestingly, after using controlled pore glass 
(CPG) with a large pore size (300 Å) as the solid support for synthesis, it was possible 
to detect the enzymatic product. Those results suggest that the large size of PFTase, a 
heterodimer of 80-90 kDa, limits the ability of the enzyme to penetrate into the 
interior of many conventional supports used for SPPS.114 While the use of CPG for 
peptide synthesis appeared to provide a viable solution to this problem, we were 
concerned that the much lower peptide loading obtainable with this material would be 
problematic when trying to identify specific peptide sequences present on a single 
bead in a one-bead-one-compound library. Thus we elected to pursue a parallel 
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synthesis strategy where peptides were synthesized on amine-functionalized cellulose 
filters (SPOT synthesis). Gratifyingly, synthesis of C-terminal peptides ending in 
CVIA using the synthetic procedure described above proceeded smoothly and analysis 
after enzymatic prenylation with FPP showed essentially quantitative conversion of 
the peptide to the corresponding farnesylated product. 
While MS analysis of peptides released from the resin after photocleavage 
worked well for the detection of prenylated peptides in the development of this 
methodology, such an approach is not ammenable to the screening of large 
libraries of peptides. Originally, we planned to use a fluorescent FPP analogue to 
accomplish this90-92; in such a strategy, spots containing actual peptide substrates 
should be fluorescently labeled in the course of enzymatic prenylation and be 
easily distinguished from those that are not substrates. However, low fluorescence 
of the membranes made the location of fluorescent spots difficult to distinguish. 
Thus, an alternative approach was used in which an alkyne-containing analogue of 
FPP101,115 was initially transferred followed by click reaction with biotin-azide and 
subsequent detection with streptavidin-AP using a chromogenic substrate. Hence, 
that procedure was used for all library screening described here. It should be noted 
that the alkyne-containing analogue employed here has a Vmax value comparable to 
that of FPP115 and that screening was performed under saturating substrate 
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conditions. 
Having validated the method for a single peptide, we prepared a 20-member 
library via manual SPOT synthesis2 in which the C-terminal residue of the CVIX 
sequence was varied to contain any of the 20 proteogenic amino acids. In the first 
experiment, upon completion of the synthesis, individual spots were excised from the 
membranes and cut in half. In each case, one half-spot was subjected to enzymatic 
prenylation with OPP-Far-alkyne followed by click reaction with biotin-azide and 
visualization with SP-AP. The remaining half-spots were used to confirm that the 
desired peptides were present on the cellulose filters (Figure 3.5).  
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Figure 3.5 MALDI analysis of peptides produced by SPOT synthesis performed to verify the 
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production of the desired product. The photocleavable moiety shown in Fig. 3B (main text) 
was used as the linker. The membranes were treated with UV light (365 nm) in CH3CN/H2O 
(v/v = 5/95). The resins were washed with CH3CN and MeOH. The combined solvents were 
removed in vacuo. The peptides (RAGCVIX) were re-dissolved in CH3CN/H2O (v/v = 5/95) 
with 0.1% TFA.  
 
In a secondary experiment for evaluating whether the peptides were prenylated, 
individual spots were cut in half after completion of the enzymatic prenylation. One 
half-spot was subjected to colorization as described above. Peptides from the other 
half-spots were photocleaved followed by analysis via MALDI-MS. (Figure 3.6).  
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Figure 3.6 MALDI analysis of peptides produced by SPOT synthesis after enzymatic 
farnesylation performed to confirm successful enzymatic processing. The photocleavable 
moiety shown in Fig. 3B (main text) was used as the linker. After enzymatic reaction, the 
membranes were treated with UV light (365 nm) in CH3CN/H2O (v/v = 5/95) to release the 
peptides. The membranes were washed with CH3CN and MeOH and the combined washes 
were evaporated in vacuo. The peptides (RAGCVIX) were re-dissolved in CH3CN/H2O (v/v 
= 5/95) with 0.1% TFA. 
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Figure 3.7 MS intensity ratio of prenylated peptides versus unprenylated peptides from 
Figure S4 performed to determine the extent of enzymatic prenylation of peptides prepared 
via SPOT synthesis. 
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For analysis of the spots subjected to prenylation and visualization with SP-AP, 
the intensity of the color was normalized to that obtained with CVIQ (Figure 3.8 and 
Figure 3.9). Based on that analysis, eight residues at the X position gave signals 
comparable to, or greater than A, including E, Q, D, N, G, M, S, and T. Of those, D 
and E did not show levels of prenylation (ratio of prenylated peptide to unprenylated 
peptide < 0.5, Figure 3.7) in the secondary MALDI-MS-based screen. Ds-GCVID 
also showed low reaction rate in a continuous spectrofluorimetric assay (Table 3.1). If 
streptavidin-horseradish peroxidase (SP-HRP) was used in lieu of SP-AP for 
screening, peptides containing D and E at the X position manifested much less signal 
suggesting that those sequences are not efficient substrates. However, the overall level 
of background staining obtained with SP-HRP was significantly greater than that 
observed with SP-AP limiting the dynamic range of the the screen. Hence, our 
preferred procedure is to employ SP-AP as the primary screen and then use SP-HRP 
in subsequent screening when necessary. 
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Figure 3.8 Screening of enzymatic prenylation of an RAGCVIX library. Each SPOT  
membrane was prenylated with OPP-Far-alkyne by PFTase, clicked with biotin-azide and 
then visualized by SP-AP in BCIP solution.  Membranes from three separate library 
syntheses and screenings are shown. 
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Figure 3.9 Evaluation of the extent of farnesylation of a RAGCVIX library of peptides. After 
synthesis, the peptides were subjected to enzymatic prenylation with an alkyne-containing 
analogue of FPP followed by click reaction with biotin-azide and subsequent reaction with 
streptavidin-AP using a chromogenic substrate. Color intensity was quantified by Image J 
software. The library was synthesized and screened three times and the average color 
intensities from the three trials are plotted here along with the SD depicted by the error bars. 
For comparison, the intensity was normalized relative to that observed with Gln at the X 
position.  
 
Ds-GCVIN DsGCVIA Ds-GCVIT 
3.60 ± 0.25 2.39 ± 0.25 2.28 ± 0.10 
Ds-GCVID Ds-GCVIK Ds-GCVLL 
 
v 
 (uM/min) 
0.033 ± 0.003 0.048 ± 0.009 0.032 ± 0.004 
Table 3.1 Evaluation of Ds-GCaaX peptides versus yFTase. Assays were performed 
using 2.4 μM dansylated peptide, 70 nM FTase, 10 μM OPP-Far-alkyne, in 200 mM Tris, pH 
7.5, 5 mM DTT, 5 mM MgCl2, 50 μM ZnCl2, and 0.040 % (w/v) n-dodecyl-ß-D-maltoside. 
 
To extend these results, we next employed automated SOPT synthesis to 
build a 17x20 CVa2X library with the X being one of the 20 proteogenic amino 
acids except Q, P, Y and a2 being one of the 20 proteogenic amino acids. The 
procedure for peptide synthesis was similar except at step (iii) where 
1,1’-carbonyldiimidazole in DMF was used for coupling.32 Mass spectrometric 
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analysis of selected peptides from the library showed the presence of the desired 
peptides with the exception of peptides containing W at the X position where some 
side products were again observed (similar to the results from the manual synthesis 
noted above). Synthesis, enzymatic prenylation and screening were performed in 
duplicate using the method described above. The intensity of the color was 
normalized to that obtained with CVIN and color coded with the most intense 
signals shown in red (Figure 3.10 and Figure 3.11). 
 
 
 
Figure 3.10 Screening of enzymatic prenylation of an RAGCVa2X library. Each membrane 
was prenylated with OPP-Far-alkyne by PFTase, clicked with biotin-azide and then visualized 
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by SP-AP in BCIP solution. Screenings from two separate membranes are shown. 
Spot identity: 
1-20: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)E 
21-40: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)D 
41-60: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)N 
61-80: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)R 
81-100: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)K 
101-120: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)H 
121-140: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)A 
141-160: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)V 
161-180: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)I 
181-200: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)L 
201-220: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)F 
221-240: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)W 
241-260: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)G 
261-280: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)C 
281-300: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)M 
301-320: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)S 
321-340: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)T 
361-377: SVI(E,D,N,R,K,H,A,V,I,L,F,W,G,C,M,S,T) 
 
 
Figure 3.11 Evaluation of the extent of farnesylation of a RAGCVa2X library of 
peptides. After synthesis, the peptides were subjected to enzymatic prenylation with an 
alkyne-containing analogue of FPP followed by click reaction with biotin-azide and 
subsequent reaction with SP-AP using a chromogenic substrate. Color intensity was 
quantified by Image J software. For comparison, the intensity was normalized relative to that 
observed with Asn at the X position. The library was synthesized and screened two times and 
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the average color intensities were color coded. Intensities below 33% are shown in white, 
tintensities between 34 to 65% are shown in yellow and tintensities above 65% are shown in 
red. 
 
Two general trends emerge from inspection of this data. First, analysis clearly 
indicates that PFTase from S. cerevisiae prefers M or S residues at the X position. 
This can be concluded from simple inspection of the number of high intensity (red) 
signals in their respective rows (Figure 3.11) or more quantitatively by comparison of 
the summation of all intensities in a given row (Figure 3.12). Such an analysis reveals 
that N, and A, and to a lesser extent, H V, F and T are also tolerated at the X position. 
A similar analysis indicates a preference for I, S, T and V residues at the a2 position 
with a number of others occurring less frequently. In addition, at the level of 
individual sequence analysis, a survey of all of the peptide sequences giving rise to 
the strongest signals (53 total in red), 17 have previously been reported to be 
substrates for the mammalian PFTase;112 only two sequences, CVID and CVIE, that 
are not good substrates appeared as strong signals (as noted above). Additionally, 38 
out of the 53 sequences are predicted to be substrates for the related human PFTase 
using the computer algorithm PrenPS116 (Figure 3.13). Moreover, of the 15 
non-substrate sequences predicted by PrenPS, two have been evaluated in vitro; both 
of those have been shown to be effective substrates. Hence, we conclude that the 
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strategy described here using C-terminal peptide libraries generated by robotic spot 
synthesis can be used to identify bona fide substrate sequences. 
 
  
Figure 3.12 Analysis of preferred residues at the X position and a2 position for a 
Ca1a2X-box obtained from screening of a 340-member library of peptides.  Left (A): 
Preferences for the X position.  Right (B): Preferences for the a2 position.  These 
preferences were determined by summing the intensities obtained for a single residue 
at the X or a2 position across all possible combinations at the adjacent position.  For 
example, to calculate the preference for E at the X position, all intensity values 
present in the “E” row in Fig. 3 were summed (7+2+3+2+22 etc).  To calculate the 
preference for A at the a2 position, all intensity values present in the “A” column in 
Fig. 3 were summed (7+3+57+3+11 etc).  
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sequence Screening 
value 
PrePS Kinetic 
assay6
sequence Screening 
value 
PrePS Kinetic 
assay6
CVAM 95 -3.2 (-) NA CVFA 66 -3.6 (-) NA 
CVAS 79 -3.6 (-) NA CVPM 67 -0.4 (+) NA 
CVNM 95 -3.3 (-) NA CVPS 76 -0.7 (+) NA 
CVNS 80 -3.6 (-) NA CVSN 70 -4.0 (-) NA 
CVCN 80 -3.6 (-) NA CVSH 70 -2.0 (+) NA 
CVCA 74 -0.9 (+) Sub CVSA 77 -1.3 (+) NA 
CVCM 77 -0.5 (+) NA CVSF 70 -1.6 (+) NA 
CVCS 83 -0.9 (+) NA CVSM 94 -0.9 (+) NA 
CVQM 91 0.4 (++) MTO CVSS 87 -1.3 (+) STO 
CVQS 89 0.2 (++) NA CVTN 104 -2.7 (-) NA 
CVGM 68 -3.2 (-) NA CVTH 76 -0.7 (+) NA 
CVHA 68 -3.7 (-) NA CVTA 104 -0.0 (+) Sub 
CVHM 78 -3.7 (-) NA CVTV 79 -0.7 (+) NA 
CVHS 73 -3.7 (-) MTO CVTF 79 -0.4 (+) NA 
CVIE 82 -1.3 (+) Sub CVTC 70 0.2 (++) NA 
CVID 77 -1.9 (+) NA CVTM 103 0.4 (++) NA 
CVIN 100 -1.6 (+) Sub CVTS 99 0.0 (++) NA 
CVIA 81 1.1 (++) Sub CVTT 70 -0.7 (+) MTO 
CVIM 81 1.4 (++) Sub CVYM 81 -4.1 (-) NA 
CVIS 84 1.1 (++) Sub CVVE 74 -1.7 (+) NA 
CVIT 73 0.5 (++) Sub CVVN 73 -2.1 (-) MTO 
CVLN 84 -2.4 (-) NA CVVH 68 -0.2 (+) NA 
CVLA 78 0.3 (++) Sub, 
MTO 
CVVA 78 0.6 (++) Sub 
CVLM 78 0.6 (++) NA CVVM 99 0.9 (++) Sub 
CVLS 79 0.3 (++) Sub CVVS 89 0.6 (++) NA 
CVMM 71 -0.3 (+) NA CVVT 68 -0.1 (+) MTO 
CVFN 70 -6.5 (--) NA      
Figure 3.13 Comparison of our screening result with Prenylation Prediction Suite and the 
kinetic assay performed before. Only peptides sequences giving the high intensity from the 
screening are included in this table. For the Prenylation Prediction Suite, the upstream 
sequence of the Ca1a2X is GGLLBBQFRAG. For the kinetic assay, NA means sequences not 
measured, Sub means Ca1a2X sequences from known farnesylated proteins, MTO means 
sequences exhibit multiple-turnover activity and STO means sequences exhibit 
single-turnover activity. 
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3.3 Conclusion  
From a biological perspective, it should be noted that in previous work, 
CaaX-box sequences where X is A, M, Q or S have been shown to be prenylated by 
PFTase from S. cerevisiae;109 however, N and T have not been reported as substrates 
for the yeast enzyme. These results highlight the utility this library approach for 
exploring the sequence specificity of PFTase and other enzymes involved in the 
subsequent processing of prenylated proteins. Efforts to employ such arrays to probe 
the specificity of the prenyltransferases and other prenylated protein processing 
enzymes are introduced in the next chapter. 
 
3.4 Materials and methods 
(a) General 
All synthetic reactions were carried out at 25oC and stirred magnetically unless 
otherwise noted. TLC was performed on precoated (250 mm) silica gel 60 F-254 
plates (Merck). Plates were visualized by staining with KMnO4 or hand-held UV 
lamp.  Flash chromatography silica gel (60–200 mesh, 75–250 µm) was obtained 
from Mallinckrodt Inc. Deuterated NMR solvents were purchased from Cambridge 
Isotope Laboratories, Inc. Biotin-azide was purchased from ChemPep. All amino 
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acids and peptide coupling reagents were purchased from NovaBiochem. Other 
general reagents, including salts and reagents, were purchased from Sigma-Aldrich. 
1H NMR spectra were obtained at 300 MHz; 31P NMR spectra were obtained at 121 
MHz. All NMR spectra were acquired on Varian instruments at 25°C. Chemical shifts 
are reported in ppm and J values are in Hz. SPOT synthesizer is ResPep SL obtained 
from INTAVIS Bioanalytical Instruments. Fluorescence assay data were obtained by 
using a Varian Cary Eclipse Fluorescence Spectrophotometer. Analytical HPLC was 
performed on a Beckman model 125/166 instrument, equipped with a diode array UV 
detector, ABI Analytical Spectroflow 980 fluorescence detector, and a Varian C18 
column (Microsorb-MV, 5 µm, 4.6x250 mm). Preparative HPLC separations were 
performed by using a Beckman model 127/166 instrument, equipped with a UV 
detector and a Phenomenex C18 column (Luna, 10 µm, 10x250 mm). Fluorescence 
scanning was done by Storm 840 Phosphor-Chemifluorescence Workstation 
(excitation 450 nm & emission 540-560 nm). MS spectra for small molecules were 
obtained on a Bruker BioTOF II instrument. MS spectra for peptide libraries were 
obtained on an AB Sciex 4800 MALD TOF/TOF or Bruker Biflex III instrument. 
Yeast PFTase117, Ds-GCVIA1 and OPP-Far-alkyne115 were prepared as previously 
described. OPP-Ger-NBD was prepared using a reported reaction procedure.3 
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Analogues used to screen peptide libraries for PFTase activity. 
 
(b) Synthesis of the photocleavable linker 
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Scheme S3.1 Synthesis of the photocleavable linker used for library synthesis.  Reagents 
and conditions: (i) Br2, 1,4-dioxane, room temp, 3 h; (ii) NaBH4, H2O/1,4-dioxane, 0 oC to RT, 
1.5 h, then NaOH(aq), RT, 15 min; (iii) NaN3, NH4Cl, EtOH/H2O, reflux, 12 h; (iv) PPh3, THF, 
0 oC to RT, 2 h, then H2O, RT, 12 h; (v) Dde-OH, CH2Cl2, RT, 18 h; (vi) p-nitrophenyl 
chloroformate, pyridine, CH2Cl2, RT, 350 min. 
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O-nitrophenacyl bromide (S3-2) 
Steps (i) and (ii) were performed according to a previously published procedure.4 
A solution of Br2 (4.5 mL, 87.6 mmol) in dioxane (80 mL) was added dropwise over a 
30 min period to a solution of o-nitroacetophenone (S3-1) (14.44 g, 87.4 mmol) in 
dioxane (40 mL). After the addition was completed, the mixture was stirred for 2.5 h. 
The solvent and HBr formed were removed by rotary evaporation followed by the 
addition of H2O (60 mL). The solution was extracted with Et2O (3×50 mL) and the 
combined organic layers were dried with MgSO4 and concentrated by rotary 
evaporation to yield S3-2 as a brown oil. Crude compound (2) was used without 
further purification. 1H NMR (CDCl3): δ 4.30 (s, 2H), 7.51 (dd, J = 1.5, 7.2, 1H), 7.68 
(ddd, J = 1.8, 7.8, 8.4, 1H), 7.80 (ddd, J = 1.2, 7.5, 7.5 1H), 8.24 (dd, J = 1.2, 8.4, 
1H). 
 
O-nitroepoxystyrene (S3-3) 
A suspension composed of NaBH4 (3.31 g, 87.4 mmol) and H2O (30 mL) was 
added dropwise to a solution of o-nitrophenacyl bromide (S3-2) (prepared in previous 
step) in dioxane (30 mL) over a 40 min period at 0 °C with stirring. The mixture was 
stirred at 0 oC for 40 min and then at RT for 70 min. An aqueous solution of NaOH 
(4.14 g / 30 mL) was added to the mixture. The mixture was stirred at RT for 15 min. 
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H2O (40 mL) was then added and the solution was extracted with Et2O (3×50 mL). 
The combined organic layers were dried with MgSO4 and concentrated by rotary 
evaporation. The resulting oil was purified by silica gel column chromatography (1:60 
Et2O/hexanes containing 2% Et3N) to yield S3-3 as a yellow solid (8.63 g, 59.8% 
yield). 1H NMR (CDCl3): δ 2.68 (dd, J = 2.7, 5.4, 1H), 3.30 (dd, J = 4.5, 5.7, 1H), 
4.49 (dd, J = 2.7, 4.5, 1H), 7.48 (ddd, J = 1.8, 6.9, 6.9, 1H), 7.65 (m, 2H), 8.16 (dd, J 
= 1.2, 8.4, 1H). 
 
2-azido-1-(2-nitrophenyl)ethanol (S3-4) 
To a mixture of compound (S3-3) (8.63 g, 52.3 mmol) in EtOH (70 mL) was 
added NaN3 (4.08 g, 62.8 mmol), NH4Cl (2.87 g, 53.7 mmol) and then water (70 mL). 
The mixture was stirred at reflux for 16 h. EtOH was removed by rotary evaporation. 
H2O (40 mL) was added and the solution was extracted with Et2O (3×50 mL). The 
combined organic layers were dried with MgSO4 and concentrated by rotary 
evaporation. The resulting oil was purified by silica gel column chromatography (1:3 
Et2O/hexanes) to yield S3-4 as a yellow oil (4.41 g, 40.5% yield). 1H NMR (CDCl3): 
δ 3.46 (dd, J = 7.5, 12.3, 1H), 3.76 (dd, J = 3.0, 12.3, 1H), 5.51 (dd, J = 3.3, 7.2, 1H), 
7.50 (ddd, J = 1.5, 8.4, 8.4, 1H), 7.71 (ddd, J = 1.2, 7.5, 7.5, 1H), 7.92 (dd, J = 1.5, 
7.8, 1H), 8.02 (dd, J = 1.2, 8.4, 1H). 
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2-amino-1-(2-nitrophenyl)ethanol (S3-5) 
Compound S3-4 (4.41 g, 21.2 mmol) was dissolved in dry THF (35 mL). The 
mixture was placed under an N2 (g) atmosphere and cooled to 0 oC. PPh3 (5.85 g, 22.3 
mmol) was added to this mixture, stirred at 0 oC for 10 min and then RT for 110 min. 
H2O (3 mL) was added to this mixture which was then stirred at RT for 16 h. Et2O (50 
mL) was added and the solution was extracted with 1M HCl (2×35 mL). The aqueous 
layers were combined, adjusted to a basic pH with NaOH(s) and extracted with Et2O 
(3×40 mL). The combined organic layers were dried with MgSO4 and concentrated by 
rotary evaporation to yield compound S3-5 as a yellow solid that was used without 
further purification. 1H NMR (d6-acetone): δ3.79 (dd, J = 7.2, 12.3, 1H), 5.29 (dd, J = 
5.7, 6.6, 1H), 7.54 (ddd, J = 1.5, 7.8, 8.7, 1H), 7.72 (ddd, J = 1.2, 7.2, 8.7, 1H), 7.89 
(dd, J = 1.2, 7.8, 1H), 8.02 (dd, J = 1.2, 8.1, 1H). 
 
2-(1-(2-hydroxy-2-(2-nitrophenyl)ethylamino)ethylidene)-5,5- 
dimethylcyclohexane-1,3-dione (S3-6) 
Preparation of Dde-OH: Dimedone (5.0 g, 0.0357 mol) was dissolved in DMF 
(75 mL) with HOAc (2.0 mL, 34.9 mmol), DCC (7.38 g, 35.8 mol), and DMAP (4.36 
g, 35.7 mmol) and allowed to react for 16 h. Precipitating dicyclohexylurea (DCU) 
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was removed by filtration, and the solvent was evaporated in vacuo. After dissolution 
in EtOAc (50 mL) and washed with 1M HCl (2×50 mL) and subsequently with H2O 
(2×50 mL), the organic phase was dried over MgSO4, filtered and concentrated to 
give a yellowish liquid that slowly solidified upon standing. 1H NMR (CDCl3): δ 1.08 
(s, 6H), 2.36 (s, 2H), 2.53 (s, 2H), 2.61 (s, 3H). ESI-MS [M-H+]: m/z calc. for 
C10H13O3-: 181.0870; found:181.0852. 
Protection with Dde-OH: Compound S3-5 (1.48 g, 8.15 mmol) was stirred with 
Dde-OH (1.45 g, 7.96 mmol) in 20 mL CH2Cl2 at RT for 16 h. Some CH2Cl2 was 
removed by rotary evaporation and the resulting mixture was purified by silica gel 
column chromatography (3:1 Et2O/hexanes) to yield S3-6 as a yellow solid (2.06 g, 
73.1 %). 1H NMR (CDCl3): δ 0.97 (s, 6H), 2.27 (s, 4H), 2.53 (s, 3H), 3.98 (m, 2H), 
5.55 (dd, J = 3.3, 7.5, 1H), 7.54 (ddd, J = 7.5, 7.5, 1H), 7.72 (dd, J = 7.8, 7.8, 1H), 
8.02 (m, 2H). ESI-MS [M+Na+]: m/z calc. for C18H22N2O5Na+: 369.1421; found: 
369.1480. 
 
2-(1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethylamino)-1- 
(2-nitrophenyl)ethyl 4-nitrophenyl carbonate (S3-7) 
To a solution of compound S3-6 (0.454 g, 1.31 mol) in CH2Cl2 (5 ml) was added 
4-nitrophenyl chloroformate (0.394 g, 1.95 mmol) and pyridine (0.19 ml, 2.35 mmol). 
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The mixture was stirred at room temperature for 350 min. Some CH2Cl2 was removed 
by rotary evaporation and the resulting mixture was purified by silica gel column 
chromatography (3:1 Et2O/hexanes) to yield S3-7 as a white solid (0.487 g, 72.7 %). 
1H NMR (CDCl3): δ 1.047 (s, 6H), 2.36 (s, 2H), 2.43 (s, 2H) 2.57 (s, 3H), 3.97 (dd, J 
= 5.7, 14.4, 1H), 4.22 (dd, J = 3.3, 9.6, 1H), 6.50 (d, J = 4.2, 1H), 7.38 (d, J = 9.6, 2H), 
7.61 (dd, J = 8.1, 8.1, 1H), 7.88 (m, 2H), 8.14 (d, J = 8.1, 1H), 8.25 (d, J = 7.8, 2H). 
ESI-MS [M+H+]: m/z calc. for C25H26N3O9+: 512.1664; found: .512.1591. 
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(c) Synthesis of inverted peptides 
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Scheme S3.2 Synthesis of inverted peptides. Reagents and conditions: (i) standard DIC 
coupling (2×), then, capping, then 20% piperidine, then BPB staining; (ii) standard DIC 
coupling (2×); (iii) 0.5 M Fmoc-Aa and 0.5 M 6-Cl-HOBt in DMF/CH2Cl2, 0.5 M DIC in 
CH2Cl2, 0.2 M DMAP in CH2Cl2, (6-8×), then, capping, then 20% piperidine, then BPB 
staining; (iv) standard DIC coupling (2×), then, capping, then 20% piperidine, then BPB 
staining; (v) 0.5 M photocleavable linker, 0.5 M Et3N in DMF (3-4×); (vi) 2% NH2NH2; (vii) 
0.05 M BOP, 0.05 M 6-Cl-HOBt and 0.1 M DIEA in DMF (2×); (viii) modified reagent K. 
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Amino acid residues used in the library synthesis 
Abbreviation Chemical name Abbreviation Chemical name 
B Fmoc-β-Ala-OH K Fmoc-Lys(Boc)-OH 
L Fmoc-Leu-OH H Fmoc-His(Trt)-OH 
R Fmoc-Arg(Pbf)-OH P Fmoc-Pro-OH 
A Fmoc-Ala-OH F Fmoc-Phe-OH 
G Fmoc-Gly-OH Y Fmoc-Tyr(tBu)-OH 
C Fmoc-Cys(Trt)-OH W Fmoc-Trp(Boc)-OH 
V Fmoc-Val-OH M Fmoc-Met-OH 
I Fmoc-Ile-OH S Fmoc-Ser(tBu)-OH 
Q Fmoc-Gln(Trt)-OH T Fmoc-Thr(tBu)-OH 
D Fmoc-Asp(OtBu)-OH Fmoc-Glu(OtBu)-OH 
N Fmoc-Asn(Trt)-OH 
E 
Fmoc-Glu-ODmab 
(For cyclization) 
 
Manual synthesis: 
The inverted peptides were synthesized on amino-functionalized cellulose 
membranes (0.40 mmol/g). All of the manipulations were performed at RT unless 
otherwise noted. The peptides were synthesized by spotting 1 μL of 0.5 M 
Fmoc-amino acid and 1 μL of 0.5 M DIC in DMF. The coupling reaction was 
typically allowed to proceed for 30 min twice. The membrane was incubated with 2% 
(v/v) Ac2O in DMF (capping solution A) for 5 min, followed by 2% (v/v) acetic 
anhydride, 2% (v/v) DIEA in DMF (capping solution B) for 15 min without shaking. 
The membrane was then washed with DMF (3×). The Fmoc groups were removed by 
treatment twice with 20% piperidine in DMF (5+5 min) followed by washing of the 
membrane with DMF (4×) and MeOH (2×). The membrane was then stained with 
BPB in MeOH (40 mg/L) to visualize the spot locations. The membrane was then 
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washed with MeOH (4×) and Et2O (2×).  
Next, HMPA was coupled to the growing peptide chain using the above 
procedure. The membrane was washed with MeOH (4×), diethyl ether (2×) without 
capping.  
Next, esterification of the links which will be the C-terminal residue in the final 
product was accomplished by spotting sequentially 1 μL of 0.5 M Fmoc-amino acid, 
6-Cl-HOBt in DMF/CH2Cl2 (v/v = 50:50), 1 μL of 0.5 M DIC in CH2Cl2 and 1 μL of 
0.2 M DMAP in CH2Cl2. Each coupling reaction was typically allowed to proceed for 
30 min. The process was repeated for six to eight times. The membrane was then 
incubated with capping solution A for 5 min followed by capping solution B for 15 
min without shaking. The membrane was washed with DMF (3×) and the Fmoc group 
was removed by treatment twice with 20% piperidine in DMF (5+5 min). The 
membrane was washed with DMF (4×), MeOH (2×). The membrane was stained with 
BPB in MeOH (40 mg/L) to indicate spot locations. The membrane was washed with 
MeOH (4×) followed by Et2O (2×). 
To add the photocleavable linker, 1 μL of 0.5 M photocleavable linker solution 
and 1 μL of 0.5 M Et3N in DMF were spotted onto the membrane. The coupling 
reaction was typically repeated three to four times with each time to proceed for 30 
min.  
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Next, the Dmab and Dde protecting groups were removed by treatment with 2% 
hydrazine solution in DMF (3×10 min) followed by washing with DMF and MeOH. 
For peptide cyclization, a solution of (BOP)/6-Cl-HOBt/DIEA (0.05 M, 0.05 M, 
0.1 M respectively) in DMF was mixed with the membrane. This reaction was 
performed twice, the first time for 2 h and the second time for 16 h. The membrane 
was washed with DMF (3×), MeOH (2×) and Et2O (2×).  
The membrane was treated with a modified reagent K (6.5% phenol, 5% H2O, 
5% thioanisole, 2.5% ethanedithiol, 1% anisole, and 1% triisopropylsilane in TFA) 
for 2 h for ester cleavage (ring opening) and side-chain deprotection. 
SPOT Synthesizer: 
The peptides were synthesized by ResPep SL SPOT-robot (INTAVIS 
Bioanalytical Instruments). The synthesis started with spot definition by a standard 
protocol followed by the coupling of a solution of 0.11 μL of Fmoc-amino acid (0.5 
M), 0.055 μL of DIC (1.1 M) and 0.055 μL of 6-Cl-HOBt (1.2 M) in DMF (double 
coupling, 10 and 15 min reaction each). The membrane was acetylated with acetic 
anhydride in DMF (2%), washed with DMF (3×) and EtOH (3×) and finally air-dried. 
Fmoc was removed by 20% piperidine in DMF (3×). After HMPA was coupled to the 
growing peptide chain using the above procedure, the membrane was washed with 
DMF (3×), EtOH (3×) without capping. 
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For ester-bond formation (step iii), 0.22 μL of solution Fmoc-amino acid (0.4M) 
activated with 1,1’-carbonyldiimidazole (CDI, 3 equiv.) in DMF were spotted on the 
membrane (4× coupling, 15 min reaction time each). 
To add the photocleavable linker, 0.22 μL of 0.5 M photocleavable linker 
solution mixed with Et3N (2 equiv.) in DMF were spotted onto the membrane (4× 
coupling, 15 min reaction time each). 
The procedure of peptide cyclization, side-chain cleavage and other steps was the 
same as manual synthesis. 
 
(d) MALDI MS analysis of peptides obtained via SPOT synthesis before and 
after enzymatic prenylation 
Each spot membrane was incubated with 500 μL CH3CN/H2O (v/v = 5/95) in a 
microcentrifuge tube. Peptide release was accomplished by shining UV light (λ = 365 
nm) on the side of the tube for 1 h. After photolysis, the solvent was transferred to a 
new microcentrifuge tube. The membrane was washed with 500 μL CH3CN and then 
500 μL MeOH. The combined solution was concentrated in vacuo. The resulting 
residue was dissolved in 70 μL CH3CN/H2O (v/v = 5/95) with 0.1% TFA. In a typical 
MALDI experiment, 0.7 μL of peptide solution was mixed with 0.7 μL CHCA matrix 
(10 mg/mL; CH3CN/H2O (v/v = 50/50) with 0.1% TFA) on the MALDI target and air 
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dried. 
 
(e) Screening for PFTase specificity with OPP-Far-alkyne 
Spots from manual synthesis: 
Spots from the membranes produced above were excised and incubated with 155 
mM DTT for 1 h and then washed with H2O (1×). Typical conditions for PFTase 
reactions were 5.1 mM DTT, 5 mM MgCl2, 50 µM ZnCl2, 200 mM Tris (pH=7.5), 1 
mg/mL BSA, 260 µM OPP-Far-alkyne, 0.09 mg/mL PFTase. The membranes were 
incubated in the solution for 30 min before adding OPP-Far-allkyne and PFTase. The 
enzymatic reactions were typically allowed to proceed for 4 h followed by washing 
with 25 mM NH4HCO3(aq) (4×), CH3CN (4×) after which the membranes were 
transferred to new 1.5 mL microcentrifuge tubes. 
Typical conditions for click reactions were 0.1 mM biotin-azide, 1 mM TCEP, 
0.2 mM TBTA, 1 mM CuSO4 in PBS buffer 1 (137 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4, 2mM KH2PO4, pH=7.4). The reaction was typically allowed to proceed for 
16 h. After the reactions, the membranes were washed with H2O (4×), DMF (4×) and 
placed in new tubes. 
The membranes were incubated with 5 % milk in PBS buffer 2 (100 mM 
KH2PO4, 500 mM NaCl, pH=6.5) for 1 h and then incubated with SP-AP in 5% milk 
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PBS buffer 2 (v/v = 1/800) for 30 min. After the reactions, the membranes were 
washed with PBS buffer 2 (7×) and placed in new tubes. Upon addition of 750 μL of 
buffer E (5 mM MgCl2, 20 µM ZnCl2, 100 mM NaCl, 30 mM Tris, pH=8.5) and 50 
μL of 5 mg/mL BCIP solution, turquoise color developed on positive spots after 1 h. 
The staining was terminated by adding 200 uL of 10 M HCl. 
Spots from SPOT synthesizer: 
The whole membrane was incubated with 155 mM DTT for 1 h and then washed 
with H2O (1×). Typical conditions for PFTase reactions were 5.1 mM DTT, 5 mM 
MgCl2, 50 µM ZnCl2, 100 mM Tris (pH=7.5), 1 mg/mL BSA, ~100 µM 
OPP-Far-alkyne, 0.045 mg/mL PFTase. The enzymatic reactions were typically 
allowed to proceed for 4.5 h followed by washing with 25 mM NH4HCO3(aq) (3×), 
CH3CN (3×), and H2O (3×). 
Typical conditions for click reactions were 0.1 mM biotin-azide, 1 mM TCEP, 
0.2 mM TBTA, 1 mM CuSO4 in PBS buffer 1. The reaction was typically allowed to 
proceed for 16 h. After the reactions, the membranes were washed with H2O (3×), 
DMF (3×), and H2O (3×). 
The membranes were incubated with 5 % milk in PBS buffer 2 for 1 h and then 
incubated with SP-AP in 5% milk PBS buffer 2 (v/v = 1/800) for 30 min. After the 
reactions, the membranes were washed with H2O (9×). Upon addition of BCIP 
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solution in buffer E (0.313 mg/mL), turquoise color developed on positive spots after 
1.5 h. The staining was terminated by washing with H2O (2×) and CH3CN (1×). 
 
The quantification of color intensity was performed using Image J software. The 
membrane was scanned and saved. The file was opened by Image J. Under 
Image>Type, 8-bit was selected to convert the image to grayscale. Under the menu 
Process>Subtract Background, the rolling ball radius was set to 50. Under 
Analyze>Set Measurements, the Area, Mean Gray Value, and Integrated Density were 
selected. Under Analyze>Set Scale, “pixels” in the box next to Unit of length were 
selected. Under Edit>Invert, the colors on the image were inverted, a line was drawn 
around the image boundary and the measurement of the selected are was then 
performed using the “m” key. 
 
(f) Kinetic analysis of individual peptides for substrate verification 
The rates of farnesylation of individual purified peptides by PFTase were 
determined using the time-dependent increase in fluorescence (λex 340 nm, λem 510 
nm) upon prenylation of a dansylated form of the peptide. Assays were performed 
with 2.4 μM dansylated peptide, 70 nM PFTase, 10 μM OPP-Far-alkyne, 200 mM 
Tris, pH 7.5, 5 mM DTT, 5 mM MgCl2, 50 μM ZnCl2, and 0.040 % (w/v) 
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n-dodecyl-ß-D-maltoside at 25 °C. Peptides were incubated in reaction buffer for 5 
min prior to initiation by the addition of PFTase. Fluorescence was measured as a 
function of time to define both the initial linear velocity and the reaction end point. 
The total fluorescence change observed upon reaction completion was divided by the 
initial concentration of the peptide substrate in a given reaction to yield a conversion 
from fluorescence units to product concentration (Ampconv). The linear initial rate, V, 
in fluorescence intensity per minute, was then converted to a velocity (μM product 
produced per minute) by dividing V with Ampconv. 
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Chapter 4: Rapid Analysis of Protein Farnesyltransferase Substrate 
Specificity Using Peptide Libraries and Isoprenoid Diphosphate Analogues 
 
4.1 Introduction 
In the last chapter and previous work, we reported the screening of a library of 
peptides for catalytic activity using S. cerevisiae PFTase (yPFTase).39 A similar 
strategy was used here for peptide synthesis and subsequent evaluation. Here we 
applied the SPOT synthesis method118 to study the specificity of R. norvegicus PFTase 
(rPFTase) and investigate the interplay between peptides and isoprenoid substrates of 
varying length (Figure 4.1) and the specificity of PFTases from different organisms.  
 
 
Figure 4.1 The post-translational prenylation reactions catalyzed by PFTase and 
PGGTase I and the probes used here to investigate PFTase. The ‘‘R’’ group can be a farnesyl 
or geranylgeranyl group in cells. 
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4.2 Peptide library design, synthesis and screening 
An automated SPOT synthesizer was used to create two kinds of peptide libraries 
(a 19×20 CVa2X library and a 19×20 CCa2X library with the X being one of the 20 
proteogenic amino acids except P and a2 being one of the 20 proteogenic amino acids). 
Because peptides are chemically synthesized in a C- to N-terminal direction, we 
adopted a “peptide inversion” strategy to prepare peptide libraries with free 
C-termini.31,32,44  In this approach, synthetic peptides are cyclized between their 
N-terminus and an internal carboxyl group installed on a bifunctional linker followed 
by acidolytic global deprotection and ester cleavage to yield resin-bound peptides 
with free C-termini (Figure 4.2a). To confirm the production of the desired synthetic 
peptides, a photocleavable linker was incorporated N-terminal to the Ca1a2X sequence 
so that at the end of the synthesis, individual peptide could be released from the 
membrane by UV irradiation and analyzed by MALDI. Following synthesis, each 
membrane was subjected to PFTase-catalyzed prenylation with an alkyne-containing 
FPP analogue followed by derivatization with biotin-azide via copper-catalyzed 
azide-alkyne cycloaddition (CuAAC). Those peptides that were prenylated by PFTase 
were conjugated to biotin at this step. The membrane was then subjected to an 
enzyme-linked assay involving streptavidin-alkaline phosphatase (SA-AP) and the 
chromogenic substrate 5-bromo-4-chloro-3-indolyl phosphate (BCIP). Spots 
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containing prenylated peptides appear turquoise colored, whereas spots where the 
prenylation reaction was inefficient remain colorless (Figure 4.2b). 
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Figure 4.2 Strategy for the synthesis of C-terminal Ca1a2X-box peptide libraries and 
their subsequent use to explore the specificity of PFTase. (a) Synthesis of C-terminal peptides. 
Reagents and conditions: (i) standard DIC coupling of Fmoc-Aa (2X), then capping, then 
20% piperidine; (ii) standard DIC coupling of HMPA (2X); (iii) 0.4 M Fmoc-Aa and 1.2 M 
CDI in DMF (4X), then, capping, then 20% piperidine; (iv) standard DIC coupling of 
Fmoc-Aa (2X), then capping, then 20% piperidine; (v) 0.5 M photocleavable linker, 0.5 M 
Et3N in DMF (3X); (vi) 2% N2H4; (vii) 0.05 M BOP, 0.05 M 6-Cl-HOBt and 0.1 M DIEA in 
DMF (2X); (viii) modified Reagent K. (b) Screening and imaging strategy using CVIA (a 
substrate) and CVIL (nonsubstrate) as examples. Post-reaction colorization was accomplished 
by click reaction with biotin-azide followed by incubation with SP-AP. Colorization occurred 
upon the addition of BCIP. 
 
4.3 Library screening using R. norvegicus PFTase 
In previously reported work, Fierke and coworkers studied the specificity of 
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rPFTase by synthesizing and assaying 213 Ca1a2X-box containing peptide sequences 
found in the human proteome.112 That sparse sampling of the total sequence space 
available from varying three residues (8000 possibilities) was quite useful for 
understanding prenylation specificity in the context of human biochemistry. However, 
such a study cannot reveal the complete specifity profile of the enzyme given the 
limited sampling. To complement that work, we chose to systematically assess the 
substrate specificity of mammalian PFTase at the a2 and X positions by preparing and 
screening two peptide libraries (19×20 CVa2X library and 19×20 CCa2X library) 
using R. norvegicus PFTase (rPFTase). These libraries densely sample the possible 
range of sequence space from the last two positions. Inspection of the data provided in 
Figure 4.3 confirms that many of the sequences found in the human genome including 
CVIQ, CVIM, CVIS, CVTQ, CVVQ, CVVM and CVVS are efficiently prenylated as 
was previously reported by Fierke and coworkers and references therein.112 However, 
a number of additional sequences not present in the human genome were prenylated 
with high efficiency including CVIA, CVIT, CVTS, CVVA, CVCS and others. This 
general observation is consistent with previous reports that rPFTase can prenylate 
peptide sequences not present in the genome and most of these have been 
demonstrated to be substrates using the in vitro fluorescence assay.119,120 Some of 
these sequences are found in the genomes of other organisms including S. pombe 
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(CVIA), S. commune (CVVA), D. menanogaster (CVSS), A. thaliana (CVTA), and M. 
musculus (CVAS) whose prenylated proteins have not been studied in detail. Of 
potential greater significance are sequences found in human pathogens including 
CVFQ (S. dysenteriae) and CVTH (B. circulans) as well as various herpesviruses 
(CVSS and CVPF). Recent reports suggest that in some cases, bacterially and virally 
encoded proteins must be prenylated by endogenous human prenyltransferases for 
pathogenesis.121-123 These results highlight the utility of this library approach as a tool 
for rapidly discovering/confirming new substrates. 
 
 
Figure 4.3 Heat map representation of the extent of farnesylation of a RAGCVa2X and 
RAGCCa2X library of peptides by rPFTase. Columns represent the a2 positions and rows 
represent the X positions. For each box, there are two numbers. The left and right values are 
spot intensities obtained with the CVa2X and CCa2X libraries, respectively. For comparison, 
the intensity of both libraries was normalized relative to that observed with the sequence CIIS. 
Each library was synthesized and screened at least two times and the average color intensities 
were color coded to produce the heat map. The intensities below 34% are shown in white, 
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those between 34 to 66% are shown in yellow, and those above 66% are shown in red. 
Diagonally shaded boxes represent sequences that are found in the human or rat genome.  
 
 Previously Fierke and coworkers reported that peptides containing cysteine 
as the a1 position tend to have lower multiple turnover reactivity.112 That inspired us to 
study CCa2X peptides more thoroughly using a CCa2X library. Since we had not 
previously prepared libraries containing adjacent Cys residues, a number of spots 
were selected and the peptides were cleaved from the membrane via UV irradiation 
and analyzed by MALDI MS. The spots gave the expected m/z values for the 
corresponding target peptides with an acceptable signal-to-noise ratio except when X 
was C, G or W. In screening the CCa2X library, fewer positive spots were detected 
(compared to our observations with the CVa2X library) indicating that generally 
CCa2X peptides have lower reactivity. It was previously reported that the a1 position 
of the Ca1a2X motif is more solvent exposed than the a2 and X positions, and that 
there are no apparent restrictions at this position.98 However, our screening results 
show that the a1 position does have an effect on PFTase specificity, and PFTase 
discriminates against sequences with Cys as the a1 residue unless the a2 position is Ile 
or Val, and the X position is Gln, Met or Ser. In vitro enzymatic assay of selected 
peptides also confirmed these screening results (Tables 4.3). The observations 
described here are consistent with previously reported in vivo farnesylated protein 
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sequences. For example, it has been reported that the tyrosine phosphatases PRL-1, -2, 
-3 associate with the cellular membrane or endosome in a farnesylation-dependent 
manner.124 Their C-terminal sequences are CCIQ, CCVQ and CCVM, respectively 
which also showed high reactivity in our screening analysis. As was noted above for 
the CVa2X library, the CCa2X library also contains numerous sequences that do not 
exist in the human genome but are still modified with high efficiency by rPFTase 
including CCIM, CCIS, CCTQ, and CCVS. The sequence CCSQ is particularly 
interesting since it occurs in the genome of the pathogenic bacteria N. sennetsu that 
resides within human cells; as noted above, prenylation of that protein by endogenous 
farnesyltransferase may be essential for pathogenesis. Finally, it should be noted that 
some proteins with C-terminal CCa2X sequences are farnesylated or 
geranylgeranylated on the first Cys and then palmitoylated at the second Cys (the a2 
position) in lieu of proteolytic removal of the a1a2X tripeptide.125 Thus, this study 
using a CCa2X library paves the way for the use of such libraries to probe 
palmitoylation specificity. For this, a CCa2X library could be prenylated chemically 
using orthogonally protected Cys34,35 or enzymatically with PFTase or PGGTase-I and 
then screened for enzymatic palmitoylation using an alkyne-containing 
palmitoyl-CoA analogue.126  
 Overall, the results from screening CVa2X and CCa2X libraries confirm 
 112
many of the previously reported observations concerning rPFTase specificity. 
However, importantly, the use of these peptide libraries has allowed us to identify 
numerous sequences not present in the human genome that are efficient substrates for 
rPFTase. The discovery of such sequences may be useful for biotechnology 
applications in which Ca1a2X box sequences are appended onto proteins for 
site-specific labeling and builds upon results reported by the Fierke127 and 
Hougland128 groups on altering peptide specificity and work from Nguyen et al97 on 
modulating isoprenoid substrate recognition. The ability of rPFTase to recognize 
sequences not found in the genome could serve as an important step in the 
development of orthogonal PFTase variants. Additionally given that many of the 
PFTase inhibitors created to date are peptidomimetic molecules based on Ca1a2X box 
sequences,129,130 the insights obtained from the peptide libraries described here should 
be useful for inhibitor design. Finally, the discovery of substrate sequences present in 
the genomes of bacteria and viruses may shed light on their mechanisms of 
pathogenesis and suggest new approaches for therapeutic intervention. 
 
4.4 Statistical analysis of library screening method and enzyme 
concentration dependence 
In interpreting the data from the studies described above, we focused on the 
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medium (yellow) and high (red) intensity spots. To assess the validity of those 
measurements, statistical analysis was performed using the data from the CVa2X 
library. Figure 4.4 shows the average spot intensity (from three separate experiments) 
at each position along with the standard deviation. Comparison of the percent 
standard deviation from the mean for each of the three categories (low, medium and 
high) gives values of 73, 35 and 18%, respectively. Further calculation for the 95% 
confidence interval for the same three categories yields values of 186, 88 and 44% 
suggesting that there is insufficient certainty (the uncertainty is larger than the values 
measured) in the data for the low intensity spots. Thus, this analysis suggests that 
spots that appear as yellow (medium intensity) or red (high intensity) are highly likely 
to be bona fide substrates. In contrast, it is not possible to differentiate with certainty 
whether spots that appear as white in the heat maps are poor substrates or not 
substrates at all. 
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Figure 4.4 Heat map representation of the extent of farnesylation of a RAGCVa2X 
library by rPFTase. Columns represent specific a2 positions and rows represent specific X 
positions. For each box, there are two numbers. The left and right values are spot intensities 
and standard deviations obtained from three screening experiments, respectively. For 
comparison, the intensities of both libraries were normalized relative to that observed with the 
sequence CIIS. The intensities below 34% are shown in white, those between 34 to 66% are 
shown in yellow, and those above 66% are shown in red. Diagonally shaded boxes indicate 
sequences that are found in the human or rat genome.  
 
The statistical analysis described above suggests that it is not possible to 
conclude anything concerning the low intensity substrates. To examine this in greater 
detail, the effect of using a higher enzyme concentration was explored. Thus, the 
380-member CCa2X library was screened using an enzyme concentration 3-fold 
higher than that used for the earlier experiments. Figure 4.5 summarizes the results 
obtained from screening the CCa2X library at the two different concentrations. 
Inspection of that data reveals several interesting observations. Most importantly, 
numerous spots that fell into the low intensity category at low enzyme concentration 
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moved into the medium or high category when the higher enzyme concentration was 
used including several whose intensity increased more than 2-fold. In some cases, 
sequences that were in the low intensity category increased significantly (more than 
3-fold) but that increase was not sufficient to move them into the medium class given 
their low initial intensity. Of those, it should be noted that CCQS, CCIL, CCIF, CCGY, 
CCKT, CCPC and CCVL are present in the human genome. These results suggest that 
those sequences are real but poor substrates for the rPFTase. That conclusion is 
supported by data from Hougland et al112 who did observe catalytic activity with the 
sequences CCIF and CCIL using in vitro fluorescence assays although it was 15- and 
140-fold lower, respectively, compared with that for optimal substrates. In contrast, 
for most of the white spots, no significant increase in spot intensity was observed 
when the enzyme concentration was increased 3-fold, indicating that those sequences 
are either extremely poor substrates or not substrates at all in terms of 
multiple-turnover reactions. An alternative explanation is that some of these 
sequences may be single-turnover substrates under these in vitro conditions.112 Efforts 
to explore the screening of these libraries using stoichiometric quantities of enzyme to 
reveal single-turnover substrates are in progress. Overall, this experiment 
demonstrates how the dynamic range of this screening method can be increased by 
raising the enzyme concentration and be used to detect activities that are more than 
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100-fold lower than that manifested by the fastest substrates. 
 
Figure 4.5 Evaluation of the extent of farnesylation of a RAGCCa2X library of peptides 
using different concentrations of rPFTase. Columns represent specific a2 positions and rows 
represent specific X positions. For each box, there are two values. The left and right numbers 
indicate [rPFTase] = 55 ug/mL and 182 ug/mL results, respectively. Color intensities were 
quantified by Image J software. For comparison, the intensities in the CCa2X library were 
normalized relative to that observed with the CIIS sequence. The library was synthesized and 
screened at least two times and the average color intensities were color-coded. The intensity 
below 34% is shown in white. The intensity between 34 to 66% is shown in yellow. The 
intensity above 66% is shown in red. Shaded boxes indicate the peptide sequences that are 
found in the human or rat genome. 
 
4.5 Comparison with direct kinetic analysis and bioinformatics methods 
Before using the libraries reported here in additional experiments, the results 
obtained with them in the experiments described above were compared with data 
obtained using two other methodologies. First the intensity data obtained from the 
CVa2X library screening was compared with data obtained via direct kinetic analysis 
using individually synthesized peptides. Hougland et al120 reported such data for a 
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series of peptides (n = 73) based on CVa2X where X was restricted to A, M, Q and S. 
A plot of the library screening intensity versus kcat/KM gave a statistically significant 
correlation (Figure 4.6, p < 0.001) although there is significant deviation for some 
sequences. Comparison of data from individual sequences after binning the kcat/KM 
data into low, medium and high values (Figure 4.7) allows the correlation to be easily 
visualized. Inspection of that data reveals that methionine-containing sequences (with 
M at the a2 or X position) correlate particularly poorly which may be due to oxidation 
to the sulfoxide during the synthesis and visualization process. In the MS analysis of 
selected methionine-containing peptide sequences, the sulfoxide is either the only 
detectable species or the major product present (see MS data for CCIM, Figure S4.1); 
similar results were noted in our earlier library work with yeast PFTase (with the 
sequence CVIM)39 and in other libraries currently being prepared including the 
sequences CKIM, CDIM, CTIM, CFIM, CGIM (data not shown). The library 
screening data obtained here was also compared with predictions made using PrePS, a 
web-based bioinformatics program that scores sequences for their potential to be 
PFTase substrates.131 A plot of the library screening intensity versus PrePS score gave 
a statistically significant correlation (Figure 4.8, p < 0.005). Comparison of data from 
individual sequences after binning the PrePS scores into low, medium and high values 
(Figure 4.9) shows that many sequences observed as positives in the library screening 
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are predicted to be PFTase substrates by PrePS. As noted for the kcat/KM data, 
methionine-containing sequences also correlate poorly. Conversely, the library 
screening reveals a number of sequences that are enzyme substrates that are not 
predicted by PrePS including CVFQ, CVSQ and CVYQ. Those sequences are 
particularly noteworthy since they were also identified as substrates in assays with 
individual peptides by Fierke and coworkers.120 In general, the comparisons noted 
above show that the data obtained with the peptide libraries described herein 
reproduces many of the features of substrate recognition previously reported for 
PFTase and thus underscores the validity of using these libraries for rapidly assessing 
aspects of PFTase substrate specificity. 
 
  
Figure 4.6 Comparison of intensity values obtained via library screening with kcat/KM values 
obtained from kinetic analysis performed with individual synthetic peptides reported by 
Fierke and coworkers. (A) Comparison using all data reported by Fierke and coworkers. (B) 
Comparison limited to library screening data that yielded intensity values falling into the 
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medium (34-66%) and high (67-100%) intensity categories. Data from certain 
methionine-containing sequences and other outliers are indicated. Kinetic data obtained from 
Hougland et al.120 
 
 
Figure 4.7 Comparison of screening intensities obtained using the RAGCVa2X library of 
peptides with kcat/KM values (mM-1s-1) from Hougland et al.120 For each box, two numbers are 
listed. The left and right values are spot intensities and kcat/KM values, respectively. The 
intensities below 34% are shown in white. The intensities between 34 to 66% are shown in 
yellow. The intensities above 66% are shown in red. The kcat/KM values below 19 are shown 
in white. Those between 20 to 100 are shown in yellow and those above 100 are shown in red. 
 
  
Figure 4.8 Comparison of PrePS scores with intensity values obtained via library screening or 
kcat/KM values obtained from kinetic analysis performed with individual synthetic peptides 
reported by Fierke and coworkers.120 (A) Comparison of PrePS scores with intensity values 
obtained via library screening reported here with the CVa2X library. (B) Comparison of PrePS 
scores with kcat/KM values reported by Fierke and coworkers.120 The kinetic data used for (B) 
was obtained from Hougland et al.3 To convert PrePS scores containing (+) and (-), the 
following scale was created: (+++) = 5; (++) = 4; (+) = 3; (-) = 2; (- -) = 1; (- - -) = 0. To 
obtain PrePS scores, the H-ras sequence KLNPPDESGPGCMRAGCVa2X was used where 
a2X are the residues at the a2 and X positions, respectively, since the program requires a 
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minimum peptide length of 20 residues. 
 
(a) 
 
 
(b) 
 
Figure 4.9 (a) Comparison of screening intensities from a RAGCVa2X library of peptides 
(left values) with PrePS predictions (right values). (b) Comparison of kcat/KM (mM-1s-1) values 
from Hougland paper120 (left values) with PrePS predictions (right values). To obtain PrePS 
scores, the H-ras sequence KLNPPDESGPGCMRAGCVa2X was used where a2X are the 
residues at the a2 and X positions, respectively. The intensities below 34% are shown white. 
Those between 34 to 66% are shown in yellow and those above 66% are shown in red. The 
kcat/KM values below 20 are shown in white. Those between 20 to 100 are shown in yellow 
and those above 100 are shown in red. For PrePS predictions, values of -2 to +1 are shown in 
white, values of +2 are shown in yellow and values of +3 are shown in red. 
 
4.6 Examining the interplay between peptide specificity and isoprenoid 
length 
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Inspection of the crystal structure of the ternary complex of PFTase bound to a 
peptide substrate and isoprenoid analog reveals extensive contacts between the 
isoprenoid and the peptide.98 Previously, Gibbs and coworkers observed in studies 
using a series of modified isoprenoid diphosphates that peptide substrate specificity 
varied depending on which particular isoprenoid was used.132 That is, while some 
isoprenoids worked well for certain peptide sequences, other isoprenoids worked best 
with different peptide substrates. Since a number of isoprenoid analogues are 
currently being used to probe protein prenylation in living cells99,101-103,133-135 and it 
would be useful to know whether modifications in the isoprenoid structure show 
systematic differences in peptide specificity. Similarly, isoprenoid analogues are being 
developed to disrupt interactions with prenylated proteins.96 In those cases it will be 
important to know whether such analogues are incorporated into prenylated proteins 
with a specificity profile similar to farnesyl groups. While in vitro assays with 
individual peptides do allow the catalytic efficiencies of different isoprenoid 
substrates to be compared, such experiments do not allow global variations in peptide 
substrate efficiency to be studied. To address this question for alkyne probes currently 
being used for proteomic applications, we screened a 380 member CVa2X library 
using three different isoprenoid analogues of varying length (C5-Alk, C10-Alk, 
C15-Alk, Figure 4.1). The screening data is summarized in Figure 4.10. From the 
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results, it can be seen that the specificity profiles obtained using the C10-Alk and 
C15-Alk substrates are similar.  For example, CVCS, CVHQ, CVIQ, CVIM, CVIS, 
CVTQ, CVTS, CVVQ, CVVM and other sequences manifest comparable reactivity 
with C10-Alk and C15-Alk. In some cases, C10-Alk reacts preferentially compared 
with C15-Alk (CVCQ, CVMQ, CVLM and CVLS) while in other cases C15-Alk 
reacts preferentially compared with C10-Alk (CVAF, CVIA, CVIG and CVTF).  In 
most cases, the observed differences are on the order of 2-fold making them relatively 
minor. However, in a few cases, more significant differences exist. Those include 
cases where C15-Alk exhibits preferential reactivity (CVAF, CVTF and CVVV) as 
well as a few instances where C10-Alk displays greater reactivity (CVQQ and 
CVMQ). In aggregate, similar results were obtained with these two different 
isoprenoids suggesting that probe choice does not skew results in proteomic 
investigations although care should be taken in quantitative proteomic experiments 
since significant variations in labeling do occur in a handful of cases. 
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Figure 4.10 Heat map representation of the extent of farnesylation of a RAGCVa2X 
library of peptides with different isoprenoid substrates. For each sequence, the left value 
shows the results using C5-Alk, the middle value using C10-Alk, the right value using 
C15-Alk. For comparison, the intensity was normalized relative to that observed with CVIS. 
Color coding and shading was performed as described for Figure 4.2. 
 
In contrast to the above observations, experiments with the C5-Alk gave different 
results. First, it is clear that the C5-Alk is not an efficient substrate for PFTase since 
fewer positive spots were observed in the screening experiment. A comparison of the 
kinetic constants measured with an in vitro enzyme assay using FPP, C10-Alk and 
C15-Alk (Table 4.1) shows that while the catalytic efficiencies of C10-Alk and 
C15-Alk are comparable but lower than FPP. C5-Alk is a much poorer substrate with 
KM 78-fold higher and kcat 400-fold lower compared with FPP (Table 4.2); attenuated 
catalytic activity was previously noted with that analogue using yPFTase.136 More 
importantly, the specificity profile with C5-Alk was significantly different from that 
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of the other probes. For example, CVIQ, CVIS, CVVQ and CVVS all showed high 
activity regardless of which isoprenoid probe was used. In contrast, CVCQ, CVHQ, 
CVTQ, CVAS, CVCS, and CVTS were highly reactive when using C10-Alk and 
C15-Alk but not in the presence of C5-Alk. Those results demonstrate that the peptide 
substrate selectivity obtained using C5-Alk differs significantly from that observed 
with C10-Alk and C15-Alk and suggests that this shorter probe is not suitable for 
proteomic analysis of farnesylated proteins since its peptide specificity profile is 
likely to be different than that for FPP. However, the different pattern of reactivity 
observed with C5-Alk may be useful for designing orthogonal prenyltransferases that 
recognize novel sequences. Overall, these experiments illustrate how C-terminal 
peptide libraries can be used to rapidly examine the effect of changes in isoprenoid 
structure on the prenyltransferase specificity.  
 
isoprenoid kcat (s-1) KM (uM)a kcat/KM 
(uM-1s-1)a 
kcat/KM (rel.) 
0.019 4 0.107 4 0.18 FPP 
(Literature 
value) 
0.29 ± 0.01 5 1.5 ± 0.2 5 0.19 
 
FPP 0.21 ± 0.01 0.11 ± 0.03 1.9 1 
C10-Alk 0.24 ± 0.01 0.61 ± 0.15 0.39 0.21 
C15-Alk 0.08 ± 0.004 0.14 ± 0.06 0.57 0.31 
aKM in this case is the KM for the isoprenoid substrate. 
Table 4.1 Kinetic Constants for the rPFTase-Catalyzed Reaction of FPP and analogues with 
DsGCVLS peptides. Assays were performed with 2.0 μM DsGCVLS, 20 nM rPFTase, 
varying concentrations (0.25-16 μM) of FPP analogues, 50 mM Tris, pH 7.5, 5 mM DTT, 5 
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mM MgCl2, 50 μM ZnCl2, and 0.040 % (w/v) n-dodecyl-ß-D-maltoside.  
 
rPFTase kcat (s-1) KM (uM)a kcat/ KM (s-1uM-1)a 
C5-Alk 6.3(±0.4)×10-5 12 ± 3 5.0×10-6 
FPP 1.7(±0.2)×10-2 2.5 ± 0.7 6.0×10-3 
aKM in this case is the KM for the isoprenoid substrate. 
Table 4.2 Evaluation of OrG-RTRCVIS peptides for R. norvegicus PFTase. Assays were 
performed at varying concentration of isoprenoid (0.2-20 uM FPP or 5-200 uM C5-Alk), 2.1 
μM OrG-RTRCVIS peptide, 50 nM PFTase (for FPP) or 500 nM PFTase (for C5-Alk), 50 
mM Tris, pH 7.5, 5 mM DTT, 5 mM MgCl2, 50 μM ZnCl2. Work reported from Poulter and 
coworkers indicates that OrG-GCVIA is a poorer substrate compared with DsGCVIA.6,7 
 
4.7 Probing the specificity of PFTases from different species 
Given the efficiency of the method described here for systematically and rapidly 
probing a large number of peptide sequences, we envisioned that it would be an 
effective strategy for examining the specificity of PFTase enzymes from different 
species. Thus C-terminal peptide libraries were used to compare the specificity 
between PFTases from three different species (R. norvegicus, C. albicans and S. 
cerevisiae). Accordingly, SPOT synthesis was employed to prepare the same 19×20 
CVa2X library described above followed by screening and visualization using 
C15-Alk as a substrate. The screening results are summarized in Figure 4.11. A 
random 60-member library with a1 residues different from valine was also synthesized, 
screened, and visualized as noted above (see Figure 4.12). For these experiments, 
screening was performed using an equivalent amount of enzymatic activity by 
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normalizing for differences in reaction rate using DsGCVIA (2 uM) and saturating 
concentrations of C15-Alk (100 uM). 
 
 
Figure 4.11 Heat map representation of the extent of farnesylation of a RAGCVa2X 
library of peptides by three different PFTases. Rows represent a2 position and columns 
represent X position. For each sequence (each box), there are three sections. The left, middle 
and right values indicated results obtained with R. norvegicus, C. albicans, S. cerevisiae 
PFTases, respectively. For comparison, the intensity was normalized relative to that observed 
with CVIS. Color coding was performed as described for Figure 4.2. 
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CTRK CQRK CKCI CSEI CIII CKYI CASL CTIL CSGL CAIL 
4 4 2 3 4 3 6 21 3 2 6 2 3 15 11 4 12 3 2 13 3 21 84 43 2 13 3 5 32 13
CIIL CIDL CPFW CHDE CRME CKGE CCLD CHHD CDDD CALD 
2 28 11 1 6 2 1 6 2 2 4 2 1 6 1 1 5 1 1 3 1 2 4 2 2 3 1 1 2 1
CWKD CDPN CRNR CQGK CLAK CRVK CIGK CIHH CYNA CTVA 
2 3 1 1 2 0 1 3 1 4 9 4 3 10 3 2 11 2 3 10 4 2 6 4 1 4 2 98 88 92
CSNA CPKA CYDA CNDV CMYV CFIF CIQF CNAG CCVC CSIM 
3 5 3 5 10 4 3 6 3 2 5 3 5 12 4 2 5 7 5 6 7 2 6 3 17 9 6 77 97 93
CCIM CTIM CIIM CAIM CTLM CCPS CDFS CIIS CCCS CKQS 
44 42 42 94 116 97 82 90 83 88 116 100 26 58 97 14 4 3 2 3 2 100 100 100 30 4 9 15 24 9
CIKS CTDS CKCT CKQQ CCIQ CASQ CDDY CAPY CADY CPNY 
4 10 4 2 1 1 11 47 5 38 77 46 95 62 57 75 18 74 1 3 1 2 3 2 1 2 1 2 3 1
 
Figure 4.12 Evaluation of the extent of farnesylation of a random library of peptides by 
PFTases from three different species. For each box, there are three values. The left, middle 
and right values were obtained using R. norvegicus, C. albicans, S. cerevisiae PFTase, 
respectively. Color intensities were quantified by Image J software. For comparison, the 
intensities were normalized relative to that observed with the CIIS sequence. Color coding 
was performed as described for Figure 4.2. 
 
In general, it can be seen that the three enzymes have similar peptide specificities 
(Figure 4.11). Thus, they all display a preference for Ile and Val at the a2 position, and 
Gln, Ala, Met, Ser and Thr at the X position. This is not surprising, given their 
sequence similarity. BLAST analysis of the PFTase β-subunit shows that the residues 
contacting the peptide substrate are mostly conserved (Figure 4.13). From the 
numbers of active peptides recognized by the three enzymes (Figure 4.14), several 
conclusions can be made. First, yPFTase prenylates more sequences (84, 19%) than 
the other two enzymes making it the most promiscuous of the three. In contrast, the 
 128
CaPFTase is the most selective, efficiently prenylating only 47 (11%) out of the 440 
examined; rPFTase exhibits similar overall specificity, prenylating 51 of the 
sequences (12%). Next, despite those differences in selectivity, rPFTase shares more 
substrates with yPFTase (51) than with CaPFTase (41). This observation is consistent 
with sequence alignment of the different genes. The β-subunit of rPFTase has higher 
similarity with yPFTase than with CaPFTase (58% vs 47%). Finally, there are 
significant differences between how the three different enzymes process identical 
substrates. Numerous examples occur where the C. albicans enzyme manifests higher 
relative reactivity with a given sequence. Those include CVHV, CVIV, CVLT, CVFM, 
CVPQ, CVTV, CVVV, CVVI, CVVL and CVVT which all show at least a 2-fold 
higher intensity with CaPFTase relative to rPFTase (see Figure 4.15a for data 
presented in graphical form). As an example, in vitro analysis using the peptide 
Ds-GCVVV reveals that CaPFTase exhibits a 6.2-fold greater kcat/KM value when 
compared with rPFTase (Table 4.3). Similar evidence for greater preference for 
yPFTase compared with rPFTase was also observed in this data. The sequences 
CVAM, CVNM, CVIV, CVLN, CVLA, CVLM, CVLT, CVFM, CVFT, CVPM, CVSF, 
CVSM, CVTN, CVTV, CVTY, CVYM, CVVN, CVVI, CVVL and CVVY all show at 
least a 2-fold higher intensity with yPFTase relative to rPFTase (see Figure 4.15b for 
data presented in graphical form). In vitro analysis using the peptide Ds-GCVTN 
 129
reveals that yPFTase exhibits a 11-fold greater kcat/KM value when compared with 
rPFTase (Table 4.3). While these differences reflect deviations in catalytic activity, 
they suggest that significant variations in sequence specificity occur between these 
enzymes. Such differences may be useful for the design of PFTase inhibitors that are 
selective for different species. Such inhibitors could be useful as drugs for the 
treatment of a number of diseases beyond cancer including malaria, leshmania and 
hepatitis. 
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(b) 
 
Figure 4.13 Structural comparison between β-subunits of rPFTase, CaPFTase and 
yPFTase in (a) linear sequence and in (b) 3-D structure. (a) Sequence alignment of three 
different PFTases. The residues that are close to the Ca1a2X substrate are indicated by arrows. 
The multiple sequence alignment was done using ClustalW from the ExPASy website. (b) 
CVIM peptide binding in PFTase. Only the substrate peptide Ca1a2X motif and protein 
residues involved in binding are shown. The structure was derived from the rPFTase crystal 
structure (PDB ID: 1D8D). If the corresponding residues are different in CaPFTase or 
yPFTase, those residues are superimposed in different colors. Residues from rPFTase, 
CaPFTase and yPFTase are shown in green, blue and orange, respectively. The CVIM peptide 
substrate is shown in magenta. 
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Figure 4.14 Number of peptide sequences that are recognized by three different PFTases. 
Peptides which showed high and medium intensities in the screening are grouped together. 
Low intensity spots were not considered in this analysis. 
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Figure 4.15 (a) Comparison of the intensities of selected peptide sequences which show at 
least a 2-fold higher intensity with CaPFTase relative to rPFTase from Figure 4.10. For each 
sequence, the left bar indicates the iscreening intensities by using the PFTase from R. 
norvegicus, the middle bar from C. albicans and the right bar from S. cerevisiae. (b) 
Comparison of the intensities of selected peptide sequences which show at least a 2-fold 
higher intensity with yPFTase relative to rPFTase from Figure 4.11. For each sequence, the 
left bar indicates the iscreening intensities by using the PFTase from R. norvegicus, the 
middle bar from C. albicans and the right bar from S. cerevisiae. 
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Ca1a2X Enzyme Screening 
intensity a 
kcat (s-1) KM (uM)b kcat / KM 
(uM-1s-1)b 
CCVQ 82 (or 106) (7.3±0.7)×10-2 0.89±0.30 0.082 
CCIA 
rPFTase 
52 (or 33) NAc NAc NAc 
CVIA rPFTase 73 0.14±0.01 0.74±0.29 0.19 
CVIT rPFTase 66 0.14±0.01 1.2±0.3 0.12 
CVIN rPFTase 53 0.16±0.01 1.5±0.3 0.11 
rPFTase 21 0.13±0.01 5.6±1.0 0.023 CTIL 
CaPFTase 84 1.3(±0.2) 6.1±1.6 0.21 
rPFTase 42 (7.8±0.9)×10-2 0.63±0.37 0.12 
CaPFTase 94 1.6±0.1 2.1±0.4 0.74 
 
CVVV 
yPFTase 74 2.4±0.3 4.4±1.4 0.55 
rPFTase 39 0.12±0.01 3.4±0.5 0.035 
CaPFTase 20 1.4±0.1 8.6±1.4 0.16 
 
CVVN 
yPFTase 100 1.5±0.1 1.7±0.4 0.88 
rPFTase 23 0.25±0.08 15±6 0.016 
CaPFTase 7 1.9±0.3 49±9 0.039 
 
CVTN 
yPFTase 79 2.4±0.1 14±1 0.17 
a The intensity was normalized to CIIS. The number in parentheses was obtained when a 
lower concentration of rPFTase was used. 
b KM in this case is the KM for the peptide substrate. 
c The reaction rate did not change much during the range of concentration of DsGCCIA and 
hence cannot be fit into Michaelis-Menten equation. But at 2 uM peptide concentration and 4 
uM C15-Alk, the rate of DsGCCIA is 5.3 times slower than DsGCCVQ. 
Table 4.3 Evaluation of Ds-GCaaX peptides for R. norvegicus or C. albicans PFTase. Assays 
were performed at varying concentration of dansylated peptides (1-8 μM), 50-100 nM PFTase, 
4 μM C15-Alk, 50 mM Tris, pH 7.5, 5 mM DTT, 5 mM MgCl2, 50 μM ZnCl2, and 0.040 % 
(w/v) n-dodecyl-ß-D-maltoside. 
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Figure 4.16 Plot of spot intensity versus (a) kcat, (b) KM, (c) kcat/KM from Table 4.3. The first 
two peptides data from Table S4 were excluded because their spot intensities were normalized 
differently than the others. The linear fit equation, R value and p values are shown as insets. 
 
4.8 Conclusion 
In summary, two 380-member peptide libraries (CVa2X and CCa2X libraries) 
were evaluated as substrates for R. norvegicus PFTase. That screening revealed a 
number of both known and unknown substrate sequences. Some of the latter occur in 
the genomes of bacteria and viruses and may be important for pathogenesis, 
suggesting new potential targets for therapeutic intervention. Screening of the CVa2X 
library with alkyne-functionalized isoprenoid substrates showed that those prepared 
from C10 or C15 precursors gave similar results while the analogue synthesized from a 
C5 unit gave a different pattern of reactivity. Finally the substrate specificities of 
PFTases from three organisms (S. cerevisiae, R. norvegicus and C. albicans) were 
compared using CVa2X libraries. R. norvegicus PFTase was found to share more 
peptide substrates with S. cerevisiae PFTase than with C. albicans PFTase. Overall, 
the 380-member CVa2X library was screened using three different isoprenoid 
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substrates and three different enzymes while the CCa2X library was screened using 
two different enzyme concentrations; thus over 3000 different combinations were 
evaluated. In general, this is a highly efficient strategy for rapidly probing the 
specificity of this important enzyme and should be useful for a variety of future 
studies on PFTase and related enzymes in the future. 
 
4.9 Materials and methods 
(a) General 
All synthetic reactions were carried out at 25 oC unless otherwise noted. 
Deuterated NMR solvents were purchased from Cambridge Isotope Laboratories, Inc. 
Biotin-azide was purchased from ChemPep Inc. All amino acids and peptide coupling 
reagents were purchased from P3 BioSystems or NovaBiochem. Other general 
reagents, including salts and reagents, were purchased from Sigma-Aldrich. 1H NMR 
spectra were obtained at 300 MHz; 31P NMR spectra were obtained at 121 MHz. All 
NMR spectra were acquired on Varian instruments at 25 °C. Chemical shifts are 
reported in ppm and J values are in Hz. SPOT synthesis was performed using a 
ResPep SL machine obtained from INTAVIS Bioanalytical Instruments. Fluorescence 
assay data were obtained using a Varian Cary Eclipse Fluorescence 
Spectrophotometer. Analytical HPLC was performed with a Beckman model 125/166 
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instrument, equipped with a diode array UV detector, ABI Analytical Spectroflow 980 
fluorescence detector, and a Varian C18 column (Microsorb-MV, 5 µm, 4.6 x 250 
mm). Preparative HPLC separations were performed by using a Beckman model 
127/166 instrument, equipped with a UV detector and a Phenomenex C18 column 
(Luna, 10 µm, 10 x 250 mm). MS spectra for small molecules were obtained on a 
Bruker BioTOF II instrument. MS spectra for peptide libraries were obtained on 
Bruker Biflex III instrument. 
 
(b) Synthesis of C5-Alk: 
 
Scheme S4.1. Synthesis of C5-Alk. Reagents and conditions: (i) n-BuLi, -78 oC, 1 h, then 
TBDMS, RT, 4 h, THF; (ii) PPTS, CH3OH, RT, 18 h; (iii) PBr3, Et2O, 0 oC, 45 min, then 
(nBu4N)3HP2O7, CH3CN, RT, 16 h; (iv)TBAF, CH3CN, RT, 4 h. 
 
Compounds S1-2 was made by following a previously published procedure.136 
 
Compound S1-3 
To a solution of S1-2 (5.06 mmol) in THF (5 mL) which was pre-cooled to -78 
oC was added n-BuLi (2.5 mL, 2.5 M, 6.25 mmol) dropwise. The mixture was stirred 
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at -78 oC for 1 h. A solution of TBDMSCl (0.994 g, 6.58 mmol) in THF (2.5 mL) was 
added to the above solution dropwise at -78 oC. The mixture was stirred at RT for 4 h. 
The reaction was quenched by adding H2O (25 mL). The solution was extracted with 
Et2O (2 X 25 mL) and the combined organic layers were dried with MgSO4 and 
concentrated by rotary evaporation to yield S1-3 as a colorless oil. Crude compound 
(S1-3) was used in the next step without further purification.  
 
Compound S1-4 
To a solution of S1-3 (~5.06 mmol) in CH3OH (10 mL) was added PPTS (0.175 
g, 0.759 mmol). The mixture was stirred at RT for 18 h. The solvent was removed by 
rotary evaporation and the resulting oil was purified by silica gel chromatography 
(Et2O/hexanes = 2/3) to yield S1-4 as a colorless oil (0.983 g, 76% in two steps). 1H 
NMR (CDCl3): δ 5.69 (t, J = 7.5, 1H), 4.22 (dd, J = 6, 6, 2H), 4.14 (s, 2H), 3.97 (s, 
2H), 1.71 (s, 3H), 1.59 (s, 3H), 0.94, (s, 9H), 0.11 (s, 6H). ESI-MS [M+H+]: m/z calc. 
for C14H26NaO2Si+: 277.1600; found: 277.1608. 
 
Compound S1-5 
To a solution of S1-4 (73 mg, 0.287 mmol) in Et2O (4 mL) which was pre-cooled 
to 0 oC was added PBr3 (30 uL, 0.316 mmol). The mixture was stirred at 0 oC for 55 
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min. The reaction was quenched by adding a few drops of H2O at 0 oC. Cold saturated 
NaHCO3 (15 mL) was then added. The mixture was extracted with cold Et2O (2 X 15 
mL) and the combined organic layers were dried with MgSO4 and concentrated by 
rotary evaporation to yield a colorless oil which was then dissolved in CH3CN (4 mL).  
Next, (nBu4N)3HP2O7 (0.514 g, 0.574 mmol) was added to this solution. The mixture 
was stirred at RT for 16 h. A column was filled with Dowex 50WX8 ion-exchange 
resin which was converted to the ammonium form by adding three column volumes of 
H2O/ 30% NH4OH (3:1, v/v) followed by equilibration with buffer C (25 mM 
NH4HCO3/iPrOH 49:1, v/v). The reaction was loaded onto the column and eluted 
with buffer C. The combined fractions were lyophilized and purified by preparative 
RP-HPLC with linear gradient from 25 mM NH4HCO3 to 35% CH3CN over 50 min. 
The fractions containing S1-5 were collected and lyophilized. 1H NMR 
(D2O/ND4OD): δ 5.54 (t, J = 6, 1H), 4.35 (dd, J = 7.5, 7.5, 2H), 4.02 (s, 2H), 3.88 (s, 
2H), 1.54 (s, 3H), 0.76 (s, 9H), -0.04 (s, 6H). 31P NMR (D2O/ND4OD): δ -5.83 (d, J = 
22.1, 1P), -9.83 (d, J = 22.1, 1P). ESI-MS [M-H]－: m/z calc. for C14H27O8P2Si－: 
413.0956; found: 413.0943. 
 
Compound S1-6 
Solid S1-5 from above was suspended in CH3CN (4 mL) and TBAF (200 uL, 1M, 
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0.2 mmol) was added to the solution. The mixture was stirred at RT for 190 min. 25 
mM NH4HCO3 (1 mL) was added to quench the reaction. A column was filled with 
Dowex 50WX8 ion-exchange resin which was converted to the ammonium form by 
adding three column volumes of H2O/ 30% NH4OH (3:1, v/v) followed by 
equilibration with buffer C (25 mM NH4HCO3/iPrOH 49:1, v/v). The reaction was 
loaded onto the column. The column was eluted with buffer C. The combined 
fractions were lyophilized and purified by preparative RP-HPLC with 100% 25 mM 
NH4HCO3. The fractions containing S1-6 were collected and lyophilized. 1H NMR 
(D2O/ND4OD): δ 5.56 (t, J = 7.5, 1H), 4.35 (dd, J = 7.5, 7.5, 2H), 4.01 (s, 2H), 3.88 (s, 
2H), 1.54 (s, 3H). 31P NMR (D2O/ND4OD): δ -5.82 (d, J = 22.7, 1P), -9.82 (d, J = 
22.1, 1P). ESI-MS [M-H]－: m/z calc. for C8H14O8P2－: 299.0091; found: .299.0094. 
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(c) Synthesis of inverted peptides: 
 
Scheme S4.2. Synthesis of inverted peptides for screening assay. Reagents and conditions: (i) 
standard DIC coupling (2X), then, capping, then 20% piperidine; (ii) standard DIC coupling 
(2X); (iii) 0.4 M Fmoc-Aa and 1.2 M CDI in DMF (4X), then, capping, then 20% piperidine; 
(iv) standard DIC coupling (2X), then, capping, then 20% piperidine; (v) 0.5 M 
photocleavable linker, 0.5 M Et3N in DMF (3X); (vi) 2% NH2NH2; (vii) 0.05 M BOP, 0.05 M 
6-Cl-HOBt and 0.1 M DIEA in DMF (2X); (viii) modified reagent K. 
 
SPOT Synthesis 
Amino-functionalized membranes were either purchased from INTAVIS or made 
from Whatman 540 paper.2 The TOTD (trioxa-tridecanediamine) membranes2 were 
coupled to β-Ala before usage. A 10×15 cm2 TOTD membrane was incubated with 
0.893 g Fmoc-β-Ala (2.87 mmol), 0.488 g 6-Cl-HOBt (2.87 mmol), and 443 uL DIC 
(2.87 mmol) in 20 mL DMF for 105 min. The membrane was washed with DMF 1X. 
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The membrane was incubated with 2% (v/v) AcOH in DMF for 5 min, then incubated 
with 2% (v/v) AcOH and 2% (v/v) DIEA in DMF for 15 min. The membrane was 
washed with DMF 4X. The β-Ala loading was 0.19(±0.02) umol/cm2 based on Fmoc 
assay. The membrane was incubated with 20% piperidine in DMF for 5 min 2X. The 
membrane was washed with DMF 4X, CH3OH 2X, and Et2O 2X. 
The peptides were synthesized using a ResPep SL SPOT-robot (INTAVIS 
Bioanalytical Instruments). The synthesis started with spot definition by a standard 
protocol followed by the coupling of a solution of 0.11 μL of Fmoc-amino acid (0.5 
M), 0.055 μL of DIC (1.1 M) and 0.055 μL of 6-Cl-HOBt (1.2 M) in DMF (double 
coupling, 10 and 15 min reaction each). The membrane was capped with Ac2O in 
DMF (2%), washed with DMF (3X) and EtOH (3X) and finally air-dried. Fmoc was 
removed by 20% piperidine in DMF (3X). After HMPA was coupled to the growing 
peptide chain using the above procedure, the membrane was washed with DMF (3X), 
EtOH (3X) without capping. 
For ester-bond formation (step iii), 0.22 μL of solution Fmoc-amino acid (0.4M) 
activated with 1,1’-carbonyldiimidazole (CDI, 3 equiv.) in DMF were spotted on the 
membrane (4X coupling, 15 min reaction time each). CDI was substituted by CDT if 
the amino acid was Gln or Tyr. 
To add the photocleavable linker, 0.22 μL of a DMF solution containing S 2-9 
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(0.5 M) and Et3N (1.0 M) were spotted onto the membrane (3X coupling, 15 min 
reaction time each). 
For peptide cyclization, the membrane was incubated with a solution of 
(BOP)/6-Cl-HOBt/DIEA (0.05 M, 0.05 M, 0.1 M respectively) in DMF. This reaction 
was performed twice, the first time for 2 h and the second time for 16 h. The 
membrane was washed with DMF (3X), CH3OH (2X) and Et2O (2X).  
The membrane was treated with a modified reagent K (6.5% phenol, 5% H2O, 
5% thioanisole, 2.5% ethanedithiol, 1% anisole, and 1% triisopropylsilane in TFA) for 
2 h for ester cleavage (ring opening) and global side-chain deprotection. 
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Figure S4.1 MALDI analysis of peptides produced by SPOT synthesis performed to verify 
the production of the desired product. The photocleavable moiety shown in Scheme S2 was 
used as the linker. The individual spot was treated under UV lamp (365 nm) in CH3CN/H2O 
(v/v = 5/95) for 2 h. The spots were washed with CH3CN and CH3OH. The combined solvents 
were removed in vacuo. The peptides (RAGCCIX, X≠P) were re-dissolved in CH3CN/H2O 
(v/v = 50/50) with 0.1% TFA. The m/z shown was manually calibrated by an internal standard 
(3XCCA+H+). Peptides ending with CCIC, CCIG, CCIW either had low signal intensity or 
cannot be found. 
 
(d) Screening for PFTase specificity: 
For experiments using C15-Alk, the whole membrane (10X15 cm2) was 
incubated with 155 mM DTT for 1 h and then washed with H2O (1X). Typical 
conditions for PFTase reactions were 5.1 mM DTT, 5 mM MgCl2, 50 µM ZnCl2, 50 
mM Tris-HCl (pH=7.5), 1 mg/mL BSA, ~100 µM C5-Alk, 2.7 ug/mL S. cerevisiae 
PFTase (or 55 ug/mL R. norvegicus PFTase, or 4.2 ug/mL C. albicans PFTase). The 
enzymatic reactions were typically allowed to proceed for 5 h followed by washing 
with 25 mM NH4HCO3 (3X), CH3CN (3X), and H2O (3X). 
The CCa2X library membrane was enzymatically prenylated with 55 ug/mL or 
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182 ug/mL rPFTase for 5.5 h using the same procedure as described above. 
For experiments using C10-Alk, typical conditions for PFTase reactions were 5.1 
mM DTT, 5 mM MgCl2, 50 µM ZnCl2, 50 mM Tris-HCl (pH=7.5), 1 mg/mL BSA, 
~100 µM FPP analogue, 40 ug/mL rPFTase. The enzymatic reactions were typically 
allowed to proceed for 5 h followed by washing with 25 mM NH4HCO3 (3X), CH3CN 
(3X), and H2O (3X). 
For experiments using C5-Alk, typical conditions for PFTase reactions were 5.1 
mM DTT, 5 mM MgCl2, 50 µM ZnCl2, 50 mM Tris (pH=7.5), 1 mg/mL BSA, ~100 
µM FPP analogue, 55 ug/mL rPFTase. The enzymatic reactions were allowed to 
proceed for 7.5 h followed by washing with 25 mM NH4HCO3 (3X), CH3CN (3X), 
and H2O (3X). 
Typical conditions for click reactions were 0.1 mM biotin-azide, 1 mM TCEP, 
0.2 mM TBTA, 1 mM CuSO4 in PBS buffer 1 (137 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4, 2 mM KH2PO4, pH=7.4). The reaction was typically allowed to proceed for 
16 h. After reactions, the membranes were washed with H2O (3X), DMF (3X), and 
H2O (3X). 
For detection of prenylated proteins, the membranes were incubated with 5 % 
milk in PBS buffer 2 (100 mM KH2PO4, 500 mM NaCl, pH=6.5) for ~35 min and 
then incubated with SP-AP in 5% milk PBS buffer 2 (v/v = 1/800) for ~40 min. After 
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reactions, the membranes were washed with H2O (9X). Upon addition of BCIP 
solution (0.313 mg/mL, 20 mL) in buffer E (5 mM MgCl2, 20 µM ZnCl2, 100 mM 
NaCl, 30 mM Tris, pH=8.5), turquoise color developed on positive spots after several 
hours depending on the specific library or isoprenoid. The staining reaction was 
terminated by washing with H2O (2X) and CH3CN (1X). 
The quantification of color intensity was performed using Image J software. The 
membrane was scanned and saved. The file was opened using Image J. Under 
Image>Type, 8-bit was selected to convert the image to grayscale. Under the menu 
Process>Subtract Background, the rolling ball radius was set to 50. Under 
Analyze>Set Measurements, the Area, Mean Gray Value, and Integrated Density were 
selected. Under Analyze>Set Scale, “pixels” in the box next to Unit of length was 
selected. Under Edit>Invert, the colors on the image were inverted, a line was drawn 
around the image boundary and the measurement of the selected spots was then 
performed using the “m” key. 
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Figure S4.2 Screening of enzymatic prenylation of an RAGCVa2X library. Each membrane 
was prenylated with OPP-C15-alkyne by rPFTase (55 ug/mL), clicked with biotin-azide and 
then visualized by SP-AP in BCIP solution.  
Spot identity: 
1-20: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)E 
21-40: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)Q 
41-60: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)D 
61-80: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)N 
81-100: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)R 
101-120: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)K 
121-140: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)H 
141-160: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)A 
161-180: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)V 
181-200: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)I 
201-220: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)L 
221-240: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)F 
241-260: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)Y 
261-280: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)W 
281-300: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)G 
301-320: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)C 
321-340: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)M 
341-360: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)S 
361-380: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)T 
381-399: SVI(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,S,T,W,Y,V) 
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401-410: CTRK, CQRK, CKCI, CSEI, CIII, CKYI, CASL, CTIL, CSGL, CAIL 
411-420: CIIL, CIDL, CPFW, CHDE, CRME, CKGE, CCLD, CHHD, CDDD, CALD 
421-430: CWKD, CDPN, CRNR, CQGK, CLAK, CRVK, CIGK, CIHH, CYNA, CTVA 
431-440: CSNA, CPKA, CYDA, CNDV, CMYV, CFIF, CIQF, CNAG, CCVC, CSIM 
441-450: CCIM, CTIM, CIIM, CAIM, CTLM, CCPS, CDFS, CIIS, CCCS, CKQS 
451-460: CIKS, CTDS, CKCT, CKQQ, CCIQ, CASQ, CDDY, CAPY, CADY, CPNY 
 
(a)
 
 
(b)
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Figure S4.3 Screening of enzymatic prenylation of an RAGCCa2X library. Each membrane 
was prenylated with OPP-C15-alkyne by rPFTase (55 ug/mL in (a), 182 ug/mL in (b)), 
clicked with biotin-azide and then visualized by SP-AP in BCIP solution.  
Spot identity: 
1-20: CC(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)E 
21-40: CC(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)Q 
41-60: CC(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)D 
61-80: CC(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)N 
81-100: CC(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)R 
101-120: CC(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)K 
 153
121-140: CC(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)H 
141-160: CC(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)A 
161-180: CC(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)V 
181-200: CC(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)I 
201-220: CC(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)L 
221-240: CC(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)F 
241-260: CC(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)Y 
261-280: CC(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)W 
281-300: CC(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)G 
301-320: CC(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)C 
321-340: CC(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)M 
341-360: CC(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)S 
361-380: CC(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)T 
381-399: SCI(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,S,T,W,Y,V) 
401-410: CTRK, CQRK, CKCI, CSEI, CIII, CKYI, CASL, CTIL, CSGL, CAIL 
411-420: CIIL, CIDL, CPFW, CHDE, CRME, CKGE, CCLD, CHHD, CDDD, CALD 
421-430: CWKD, CDPN, CRNR, CQGK, CLAK, CRVK, CIGK, CIHH, CYNA, CTVA 
431-440: CSNA, CPKA, CYDA, CNDV, CMYV, CFIF, CIQF, CNAG, CCVC, CSIM 
441-450: CCIM, CTIM, CIIM, CAIM, CTLM, CCPS, CDFS, CIIS, CCCS, CKQS 
451-460: CIKS, CTDS, CKCT, CKQQ, CCIQ, CASQ, CDDY, CAPY, CADY, CPNY 
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Figure S4.4 Screening of enzymatic prenylation of an RAGCVa2X library. Each membrane 
was prenylated with OPP-C15-alkyne by CaPFTase (4.2 ug/mL), clicked with biotin-azide 
and then visualized by SP-AP in BCIP solution.  
Spot identity: 
1-20: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)E 
21-40: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)Q 
41-60: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)D 
61-80: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)N 
81-100: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)R 
101-120: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)K 
121-140: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)H 
141-160: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)A 
161-180: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)V 
181-200: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)I 
201-220: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)L 
221-240: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)F 
241-260: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)Y 
261-280: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)W 
281-300: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)G 
301-320: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)C 
321-340: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)M 
341-360: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)S 
361-380: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)T 
381-399: SVI(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,S,T,W,Y,V) 
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401-410: CTRK, CQRK, CKCI, CSEI, CIII, CKYI, CASL, CTIL, CSGL, CAIL 
411-420: CIIL, CIDL, CPFW, CHDE, CRME, CKGE, CCLD, CHHD, CDDD, CALD 
421-430: CWKD, CDPN, CRNR, CQGK, CLAK, CRVK, CIGK, CIHH, CYNA, CTVA 
431-440: CSNA, CPKA, CYDA, CNDV, CMYV, CFIF, CIQF, CNAG, CCVC, CSIM 
441-450: CCIM, CTIM, CIIM, CAIM, CTLM, CCPS, CDFS, CIIS, CCCS, CKQS 
451-460: CIKS, CTDS, CKCT, CKQQ, CCIQ, CASQ, CDDY, CAPY, CADY, CPNY 
 
(a) 
 (b) 
 
 156
Figure S4.5 Screening of enzymatic prenylation of an RAGCVa2X library. Each membrane 
was prenylated with OPP-C15-alkyne by yPFTase (2.7 ug/mL), clicked with biotin-azide and 
then visualized by SP-AP in BCIP solution.  
Spot identity: 
(a) 
1-20: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)E 
21-40: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)Q 
41-60: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)D 
61-80: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)N 
81-100: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)R 
101-120: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)K 
121-140: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)H 
141-160: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)A 
161-180: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)V 
181-200: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)I 
201-220: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)L 
221-240: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)F 
241-260: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)W 
261-280: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)G 
281-300: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)C 
301-320: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)M 
321-340: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)S 
341-360: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)T 
361-370, 421-430: CTRK, CQRK, CKCI, CSEI, CIII, CKYI, CASL, CTIL, CSGL, CAIL 
371-380, 431-440: CIIL, CIDL, CPFW, CHDE, CRME, CKGE, CCLD, CHHD, CDDD, 
CALD 
381-390, 441-450: CWKD, CDPN, CRNR, CQGK, CLAK, CRVK, CIGK, CIHH, CYNA, 
CTVA 
391-400, 451-460: CSNA, CPKA, CYDA, CNDV, CMYV, CFIF, CIQF, CNAG, CCVC, 
CSIM 
401-410, 461-470: CCIM, CTIM, CIIM, CAIM, CTLM, CCPS, CDFS, CIIS, CCCS, CKQS 
411-420, 471-480: CIKS, CTDS, CKCT, CKQQ, CCIQ, CASQ, CDDY, CAPY, CADY, 
CPNY 
481-499: SVI(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,V) 
(b) 
1-20: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)E 
21-40: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)Q 
41-60: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)D 
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61-80: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)N 
81-100: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)R 
101-120: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)K 
121-140: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)H 
141-160: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)A 
161-180: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)V 
181-200: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)I 
201-220: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)L 
221-240: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)F 
241-260: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)Y 
261-280: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)W 
281-300: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)G 
301-320: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)C 
321-340: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)M 
341-360: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)S 
361-380: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)T 
381-399: SVI(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,S,T,W,Y,V) 
401-410: CTRK, CQRK, CKCI, CSEI, CIII, CKYI, CASL, CTIL, CSGL, CAIL 
411-420: CIIL, CIDL, CPFW, CHDE, CRME, CKGE, CCLD, CHHD, CDDD, CALD 
421-430: CWKD, CDPN, CRNR, CQGK, CLAK, CRVK, CIGK, CIHH, CYNA, CTVA 
431-440: CSNA, CPKA, CYDA, CNDV, CMYV, CFIF, CIQF, CNAG, CCVC, CSIM 
441-450: CCIM, CTIM, CIIM, CAIM, CTLM, CCPS, CDFS, CIIS, CCCS, CKQS 
451-460: CIKS, CTDS, CKCT, CKQQ, CCIQ, CASQ, CDDY, CAPY, CADY, CPNY 
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Figure S4.6 Screening of enzymatic prenylation of an RAGCVa2X library. Each membrane 
was prenylated with OPP-C10-alkyne by rPFTase (40 ug/mL), clicked with biotin-azide and 
then visualized by SP-AP in BCIP solution.  
Spot identity: 
1-20: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)E 
21-40: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)Q 
41-60: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)D 
61-80: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)N 
81-100: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)R 
101-120: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)K 
121-140: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)H 
141-160: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)A 
161-180: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)V 
181-200: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)I 
201-220: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)L 
221-240: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)F 
241-260: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)Y 
261-280: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)W 
281-300: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)G 
301-320: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)C 
321-340: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)M 
341-360: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)S 
361-380: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)T 
 159
381-399: SVI(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,S,T,W,Y,V) 
401-410: CTRK, CQRK, CKCI, CSEI, CIII, CKYI, CASL, CTIL, CSGL, CAIL 
411-420: CIIL, CIDL, CPFW, CHDE, CRME, CKGE, CCLD, CHHD, CDDD, CALD 
421-430: CWKD, CDPN, CRNR, CQGK, CLAK, CRVK, CIGK, CIHH, CYNA, CTVA 
431-440: CSNA, CPKA, CYDA, CNDV, CMYV, CFIF, CIQF, CNAG, CCVC, CSIM 
441-450: CCIM, CTIM, CIIM, CAIM, CTLM, CCPS, CDFS, CIIS, CCCS, CKQS 
451-460: CIKS, CTDS, CKCT, CKQQ, CCIQ, CASQ, CDDY, CAPY, CADY, CPNY 
 
(a)
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(b)
 
 
Figure S4.7 Screening of enzymatic prenylation of an RAGCVa2X library. Each membrane 
was prenylated with OPP-C5-alkyne by rPFTase (55 ug/mL), clicked with biotin-azide and 
then visualized by SP-AP in BCIP solution. (a) The membrane is from Intavis (b) The 
membrane is from Whatman540  
Spot identity: 
1-20: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)E 
21-40: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)Q 
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41-60: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)D 
61-80: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)N 
81-100: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)R 
101-120: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)K 
121-140: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)H 
141-160: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)A 
161-180: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)V 
181-200: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)I 
201-220: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)L 
221-240: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)F 
241-260: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)Y 
261-280: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)W 
281-300: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)G 
301-320: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)C 
321-340: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)M 
341-360: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)S 
361-380: CV(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V)T 
381-399: SVI(A,R,N,D,C,Q,E,G,H,I,L,K,M,F,S,T,W,Y,V) 
401-410: CTRK, CQRK, CKCI, CSEI, CIII, CKYI, CASL, CTIL, CSGL, CAIL 
411-420: CIIL, CIDL, CPFW, CHDE, CRME, CKGE, CCLD, CHHD, CDDD, CALD 
421-430: CWKD, CDPN, CRNR, CQGK, CLAK, CRVK, CIGK, CIHH, CYNA, CTVA 
431-440: CSNA, CPKA, CYDA, CNDV, CMYV, CFIF, CIQF, CNAG, CCVC, CSIM 
441-450: CCIM, CTIM, CIIM, CAIM, CTLM, CCPS, CDFS, CIIS, CCCS, CKQS 
451-460: CIKS, CTDS, CKCT, CKQQ, CCIQ, CASQ, CDDY, CAPY, CADY, CPNY 
 
(e) Kinetic analysis of individual peptides for PFTase:  
(1) Comparison of rPFTase, CaPFTase and yPFTase using Ds-GCa1a2X peptides: 
The rates of farnesylation of individual purified peptide by PFTase were 
determined using the time-dependent increase in fluorescence (λex 340 nm, λem 505 
nm) upon prenylation of a dansylated form of the peptide. Assays were performed 
with different concentrations of dansylated peptide (1, 2, 3, 5, 8 uM), 20-100 nM 
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PFTase, 4 μM C15-Alk, 50 mM Tris, pH 7.5, 5 mM DTT, 5 mM MgCl2, 50 μM ZnCl2, 
and 0.040 % (w/v) n-dodecyl-ß-D-maltoside at 25 °C. Reactions were initiated by the 
addition of PFTase. Fluorescence was measured as a function of time to define both 
the initial linear velocity and the reaction end point. The total fluorescence change 
observed upon reaction completion was divided by the initial concentration of the 
peptide substrate in a given reaction to yield a conversion from fluorescence units to 
product concentration (Ampconv). The linear initial rate, V, in fluorescence intensity 
per minute, was then converted to a velocity (μM product produced per minute) by 
dividing V with Ampconv. The initial rate was plotted with peptide concentration to 
calculate KM and kcat.  
(2) Prenylation of Ds-GCVLS with C15-Alk, C10-Alk or FPP: 
The rates of prenylation of purified peptides by rPFTase were determined using 
the time-dependent increase in fluorescence (λex 340 nm, λem 505 nm) upon 
prenylation of a dansylated form of the peptide. Assays were performed with 2.0 μM 
dansyl-GCVLS, 20 nM rPFTase, varying concentrations (0.25-16 μM) of FPP 
analogues, 50 mM Tris, pH 7.5, 5 mM DTT, 5 mM MgCl2, 50 μM ZnCl2, and 0.040 
% (w/v) n-dodecyl-ß-D-maltoside at 25 °C. Reactions were initiated by the addition of 
PFTase. Fluorescence was measured as a function of time and analyzed as described 
above. 
 163
(3) Prenylation of OrG-RTRCVIS with C5-Alk or FPP: 
Since enzymatic prenylation of dansylated peptides with C5-Alk results in 
minimal fluorescence increases, PFTase prenylation rates using C5-Alk were 
determined with an HPLC-based assay. An assay solution containing 750 uL of Tris 
(50 mM), pH 7.5, MgCl2 (12 mm), ZnCl2 (50 uM), DTT (5 mM), and OrG-RTRCVIS 
(2.4 mM) was prepared and allowed to incubate at RT for 20 min in order to ensure 
complete reduction of any disulfides. 50 uL solutions of C5-Alk were prepared so that 
when they were diluted into the assay solution the final concentration of C5-Alk was 
5.0, 10, 20, 30, 50 or 200 uM. After the alkyne-containing solutions were added into 
assay buffer, rPFTase (50 uL, 8.5 uM) was added to each centrifuge tube and the 
reaction was incubated for 4 h at RT and then each reaction was flash frozen. Each 
reaction was analyzed using an HPLC equipped with a fluorescence detector. 
Fluorescent peaks corresponding to the starting material and product were integrated 
and used to calculate the concentration of prenylated product in solution. Three 
different samples were prepared for each concentration and the average concentration 
of product from the three reactions was used to calculate KM,app and kcat,app for C5-Alk. 
A similar procedure was performed by using 0.2, 0.3, 0.5, 1.0, 3.0, and 20 mM 
concentrations of FPP. For FPP, rPFTase (50 rL, 0.85 uM) was used to initiate the 
reaction and the reaction was incubated for 20 min at RT before being flash frozen in 
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liquid nitrogen. 
 
 165
Reference 
 (1) Houghten, R. A. Proc. Natl. Acad. Sci. USA. 1985, 82, 5131. 
 (2) Hilpert, K.; Winkler, D. F. H.; Hancock, R. E. W. Nat. Protoc. 2007, 2, 
1333. 
 (3) Lam, K. S.; Salmon, S. E.; Hersh, E. M.; Hruby, V. J.; Kazmierski, W. M.; 
Knapp, R. J. Nature 1991, 354, 82. 
 (4) Edman, P. Acta Chem. Scand. 1950, 4, 283. 
 (5) Thakkar, A.; Wavreille, A.-S.; Pei, D. Anal. Chem. 2006, 78, 5935. 
 (6) Biederman, K. J.; Lee, H.; Haney, C. A.; Kaczmarek, M.; Buettner, J. A. J. 
Pept. Res. 1999, 53, 234. 
 (7) Songyang, Z.; Fanning, A. S.; Fu, C.; Xu, J.; Marfatia, S. M.; Chishti, A. H.; 
Crompton, A.; Chan, A. C.; Anderson, J. M.; Cantley, L. C. Science 1997, 275, 73. 
 (8) Vaccaro, P.; Dente, L. FEBS Lett. 2002, 512, 345. 
 (9) Vaccaro, P.; Brannetti, B.; Montecchi-Palazzi, L.; Philipp, S.; Citterich, M. 
H.; Cesareni, G.; Dente, L. J. Biol. Chem. 2001, 276, 42122. 
 (10) Stiffler, M. A.; Chen, J. R.; Grantcharova, V. P.; Lei, Y.; Fuchs, D.; Allen, J. 
E.; Zaslavskaia, L. A.; MacBeath, G. Science 2007, 317, 364. 
 (11) Shepherd, T. R.; Hard, R. L.; Murray, A. M.; Pei, D.; Fuentes, E. J. 
Biochemistry 2011, 50, 1296. 
 (12) Takashima, S.; Kitakaze, M.; Asakura, M.; Asanuma, H.; Sanada, S.; 
Tashiro, F.; Niwa, H.; Miyazaki, J.-i.; Hirota, S.; Kitamura, Y.; Kitsukawa, T.; 
Fujisawa, H.; Klagsbrun, M.; Hori, M. Proc. Natl. Acad. Sci. USA. 2002, 99, 3657. 
 (13) Staton, C. A.; Kumar, I.; Reed, M. W. R.; Brown, N. J. J. Pathol. 2007, 212, 
237. 
 (14) Becker, P. M.; Waltenberger, J.; Yachechko, R.; Mirzapoiazova, T.; Sham, J. 
S. K.; Lee, C. G.; Elias, J. A.; Verin, A. D. Circ. Res. 2005, 96, 1257. 
 (15) Acevedo, L. M.; Barillas, S.; Weis, S. M.; Göthert, J. R.; Cheresh, D. A. 
Blood 2008, 111, 2674. 
 (16) von Wronski, M. A.; Raju, N.; Pillai, R.; Bogdan, N. J.; Marinelli, E. R.; 
Nanjappan, P.; Ramalingam, K.; Arunachalam, T.; Eaton, S.; Linder, K. E.; Yan, F.; 
Pochon, S.; Tweedle, M. F.; Nunn, A. D. J. Biol. Chem. 2006, 281, 5702. 
 (17) Starzec, A.; Ladam, P.; Vassy, R.; Badache, S.; Bouchemal, N.; Navaza, A.; 
du Penhoat, C. H.; Perret, G. Y. Peptides 2007, 28, 2397. 
 (18) Berndt, N.; Hamilton, A. D.; Sebti, S. M. Nat. Rev. Cancer 2011, 11, 775. 
 (19) Moores, S. L.; Schaber, M. D.; Mosser, S. D.; Rands, E.; O'Hara, M. B.; 
Garsky, V. M.; Marshall, M. S.; Pompliano, D. L.; Gibbs, J. B. J. Biol. Chem. 1991, 
266, 14603. 
 166
 (20) Fu, H. W., and Casey, P. J. Recent Prog. Horm. Res. 1999, 54, 315. 
 (21) Hershko, A.; Ciechanover, A. Annu. Rev. Biochem. 1998, 67, 425. 
 (22) Pickart, C. M. Annu. Rev. Biochem. 2001, 70, 503. 
 (23) Deshaies, R. J.; Joazeiro, C. A. P. Annu. Rev. Biochem. 2009, 78, 399. 
 (24) Wenzel, D. M.; Stoll, K. E.; Klevit, R. E. Biochem. J. 2010, 433, 31. 
 (25) van der Veen, A. G.; Ploegh, H. L. Annu. Rev. Biochem. 2012, 81, 323. 
 (26) Hicke, L.; Schubert, H. L.; Hill, C. P. Nat. Rev. Mol. Cell. Biol. 2005, 6, 
610. 
 (27) Pai, M.-T.; Tzeng, S.-R.; Kovacs, J. J.; Keaton, M. A.; Li, S. S. C.; Yao, 
T.-P.; Zhou, P. J. Mol. Biol. 2007, 370, 290. 
 (28) Reyes-Turcu, F. E.; Horton, J. R.; Mullally, J. E.; Heroux, A.; Cheng, X.; 
Wilkinson, K. D. Cell 2006, 124, 1197. 
 (29) Williams, D. H.; Bardsley, B. Angew. Chem. Int. Ed. 1999, 38, 1172. 
 (30) Udugamasooriya, D. G.; Sharma, S. C.; Spaller, M. R. ChemBioChem 2008, 
9, 1587. 
 (31) Kania, R. S.; Zuckermann, R. N.; Marlowe, C. K. J. Am. Chem. Soc. 1994, 
116, 8835. 
 (32) Boisguerin, P.; Ay, B.; Radziwill, G.; Fritz, R. D.; Moelling, K.; Volkmer, R. 
ChemBioChem 2007, 8, 2302. 
 (33) Ay, B.; Volkmer, R.; Boisguerin, P. Tetrahedron Lett. 2007, 48, 361. 
 (34) Postma, T. M.; Giraud, M.; Albericio, F. Org. Lett. 2012, 14, 5468. 
 (35) Dekan, Z.; Mobli, M.; Pennington, M. W.; Fung, E.; Nemeth, E.; Alewood, 
P. F. Angew. Chem. Int. Ed. 2014, 53, 2931. 
 (36) Boisguerin, P.; Leben, R.; Ay, B.; Radziwill, G.; Moelling, K.; Dong, L.; 
Volkmer-Engert, R. Chem. Biol. 2004, 11, 449. 
 (37) Wiedemann, U.; Boisguerin, P.; Leben, R.; Leitner, D.; Krause, G.; Moelling, 
K.; Volkmer-Engert, R.; Oschkinat, H. J. Mol. Biol. 2004, 343, 703. 
 (38) Weski, J.; Meltzer, M.; Spaan, L.; Mönig, T.; Oeljeklaus, J.; Hauske, P.; 
Vouilleme, L.; Volkmer, R.; Boisguerin, P.; Boyd, D.; Huber, R.; Kaiser, M.; Ehrmann, 
M. ChemBioChem 2012, 13, 402. 
 (39) Wang, Y.-C.; Distefano, M. D. Chem. Commun. 2012, 48, 8228. 
 (40) Wang, Y.-C.; Dozier, J. K.; Beese, L. S.; Distefano, M. D. ACS Chem. Biol. 
2014. 
 (41) Davies, M.; Bonnat, M.; Guillier, F.; Kilburn, J. D.; Bradley, M. The J. Org. 
Chem. 1998, 63, 8696. 
 (42) Liu, R.; Marik, J.; Lam, K. S. J. Am. Chem. Soc. 2002, 124, 7678. 
 (43) Song, A.; Zhang, J.; Lebrilla, C. B.; Lam, K. S. J. Am. Chem. Soc. 2003, 
125, 6180. 
 167
 (44) Joo, S. H.; Pei, D. Biochemistry 2008, 47, 3061. 
 (45) Sweeney, M. C.; Pei, D. J. Comb. Chem. 2003, 5, 218. 
 (46) Hard, R. L.; Liu, J.; Shen, J.; Zhou, P.; Pei, D. Biochemistry 2010, 49, 
10737. 
 (47) Yao, N.; Wu, C.-Y.; Xiao, W.; Lam, K. S. Biopolymers 2008, 90, 421. 
 (48) Rajagopala, S.; Casjens, S.; Uetz, P. BMC Microbiol. 2011, 11, 213. CC BY 
4.0. http://creativecommons.org/licenses/by/4.0/ 
 (49) Yang, F.; Forrer, P.; Dauter, Z.; Conway, J. F.; Cheng, N.; Cerritelli, M. E.; 
Steven, A. C.; Pluckthun, A.; Wlodawer, A. Nat. Struct. Mol. Biol. 2000, 7, 230. 
 (50) van den Berk, L. C. J.; Landi, E.; Walma, T.; Vuister, G. W.; Dente, L.; 
Hendriks, W. J. A. J. Biochemistry 2007, 46, 13629. 
 (51) Serwer, P.; Wright, E.; Hakala, K.; Weintraub, S. BMC Res. Notes 2008, 1, 
36. CC BY 4.0. http://creativecommons.org/licenses/by/4.0/ 
 (52) Kurakin, A.; Swistowski, A.; Wu, S. C.; Bredesen, D. E. PLoS One 2007, 2, 
e953. 
 (53) Sharma, S. C.; Memic, A.; Rupasinghe, C. N.; Duc, A.-C. E.; Spaller, M. R. 
Biopolymers 2009, 92, 183. 
 (54) Teesalu, T.; Sugahara, K. N.; Kotamraju, V. R.; Ruoslahti, E. Proc. Natl. 
Acad. Sci. USA. 2009, 106, 16157. 
 (55) Stricker, N. L.; Christopherson, K. S.; Yi, B. A.; Schatz, P. J.; Raab, R. W.; 
Dawes, G.; Bassett, D. E.; Bredt, D. S.; Li, M. Nat. Biotech. 1997, 15, 336. 
 (56) Palzkill, T.; Huang, W.; Weinstock, G. M. Gene 1998, 221, 79. 
 (57) Fuh, G.; Pisabarro, M. T.; Li, Y.; Quan, C.; Lasky, L. A.; Sidhu, S. S. J. Biol. 
Chem. 2000, 275, 21486. 
 (58) Laura, R. P.; Witt, A. S.; Held, H. A.; Gerstner, R.; Deshayes, K.; Koehler, 
M. F. T.; Kosik, K. S.; Sidhu, S. S.; Lasky, L. A. J. Biol. Chem. 2002, 277, 12906. 
 (59) Held, H. A.; Sidhu, S. S. J. Mol. Biol. 2004, 340, 587. 
 (60) Tonikian, R.; Zhang, Y.; Sazinsky, S. L.; Currell, B.; Yeh, J.-H.; Reva, B.; 
Held, H. A.; Appleton, B. A.; Evangelista, M.; Wu, Y.; Xin, X.; Chan, A. C.; Seshagiri, 
S.; Lasky, L. A.; Sander, C.; Boone, C.; Bader, G. D.; Sidhu, S. S. PLoS Biol. 2008, 6, 
e239. 
 (61) Ivarsson, Y.; Arnold, R.; McLaughlin, M.; Nim, S.; Joshi, R.; Ray, D.; Liu, 
B.; Teyra, J.; Pawson, T.; Moffat, J.; Li, S. S.-C.; Sidhu, S. S.; Kim, P. M. Proc. Natl. 
Acad. Sci. USA. 2014, 111, 2542. 
 (62) Zhao, B.; Bhuripanyo, K.; Zhang, K.; Kiyokawa, H.; Schindelin, H.; Yin, J. 
Chem. Biol. 2012, 19, 1265. 
 (63) Lee, I.; Schindelin, H. Cell 2008, 134, 268. 
 (64) Zhao, B.; Bhuripanyo, K.; Schneider, J.; Zhang, K.; Schindelin, H.; Boone, 
 168
D.; Yin, J. ACS Chem. Biol. 2012, 7, 2027. 
 (65) Zhao, B.; Zhang, K.; Villhauer, E. B.; Bhuripanyo, K.; Kiyokawa, H.; 
Schindelin, H.; Yin, J. ChemBioChem 2013, 14, 1323. 
 (66) Bos, J. L. Cancer Res. 1989, 49, 4682. 
 (67) Saxena, N.; Lahiri, S. S.; Hambarde, S.; Tripathi, R. P. Cancer Invest. 2008, 
26, 948. 
 (68) Lackner, M. R.; Kindt, R. M.; Carroll, P. M.; Brown, K.; Cancilla, M. R.; 
Chen, C.; de Silva, H.; Franke, Y.; Guan, B.; Heuer, T.; Hung, T.; Keegan, K.; Lee, J. 
M.; Manne, V.; O’Brien, C.; Parry, D.; Perez-Villar, J. J.; Reddy, R. K.; Xiao, H.; 
Zhan, H.; Cockett, M.; Plowman, G.; Fitzgerald, K.; Costa, M.; Ross-Macdonald, P. 
Cancer Cell 2005, 7, 325. 
 (69) Rak, A.; Pylypenko, O.; Niculae, A.; Pyatkov, K.; Goody, R. S.; Alexandrov, 
K. Cell 2004, 117, 749. 
 (70) Winter-Vann, A. M.; Casey, P. J. Nat. Rev. Cancer 2005, 5, 405. 
 (71) Epstein, W. W.; Lever, D.; Leining, L. M.; Bruenger, E.; Rilling, H. C. Proc. 
Natl. Acad. Sci. USA. 1991, 88, 9668. 
 (72) Roskoski Jr, R. Biochem. Biophys. Res. Commun. 2003, 303, 1. 
 (73) Horiuchi, H.; Kawata, M.; Katayama, M.; Yoshida, Y.; Musha, T.; Ando, S.; 
Takai, Y. J. Biol. Chem. 1991, 266, 16981. 
 (74) Song, J. L.; White, T. C. Microbiology 2003, 149, 249. 
 (75) Chakrabarti*, D.; Azam, T.; DelVecchio, C.; Qiu, L.; Park, Y.-i.; Allen, C. M. 
Mol. Biochem. Parasit. 1998, 94, 175. 
 (76) Gelb, M. H.; Brunsveld, L.; Hrycyna, C. A.; Michaelis, S.; Tamanoi, F.; Van 
Voorhis, W. C.; Waldmann, H. Nat. Chem. Biol. 2006, 2, 518. 
 (77) Hast, M. A.; Fletcher, S.; Cummings, C. G.; Pusateri, E. E.; Blaskovich, M. 
A.; Rivas, K.; Gelb, M. H.; Van Voorhis, W. C.; Sebti, S. M.; Hamilton, A. D.; Beese, 
L. S. Chem. Biol. 2009, 16, 181. 
 (78) Hast, M. A.; Nichols, C. B.; Armstrong, S. M.; Kelly, S. M.; Hellinga, H. W.; 
Alspaugh, J. A.; Beese, L. S. J. Biol. Chem. 2011, 286, 35149. 
 (79) Sunami, S.; Ohkubo, M.; Sagara, T.; Ono, J.; Asahi, S.; Koito, S.; 
Morishima, H. Bioorg. Med. Chem. Lett. 2002, 12, 629. 
 (80) Duckworth, B. P.; Xu, J.; Taton, T. A.; Guo, A.; Distefano, M. D. 
Bioconjugate Chem. 2006, 17, 967. 
 (81) Gauchet, C.; Labadie, G. R.; Poulter, C. D. J. Am. Chem. Soc. 2006, 128, 
9274. 
 (82) Ochocki, J. D.; Distefano, M. D. MedChemComm 2013, 4, 476. 
 (83) Rashidian, M.; Song, J. M.; Pricer, R. E.; Distefano, M. D. J. Am. Chem. 
Soc. 2012, 134, 8455. 
 169
 (84) Rashidian, M.; Kumarapperuma, S. C.; Gabrielse, K.; Fegan, A.; Wagner, C. 
R.; Distefano, M. D. J. Am. Chem. Soc. 2013, 135, 16388. 
 (85) Duckworth, B. P.; Chen, Y.; Wollack, J. W.; Sham, Y.; Mueller, J. D.; Taton, 
T. A.; Distefano, M. D. Angew. Chem. Int. Ed. 2007, 46, 8819. 
 (86) Liu, X.-h.; Prestwich, G. D. J. Am. Chem. Soc. 2002, 124, 20. 
 (87) Liu, X.-h.; Prestwich, G. D. Bioorg. Med. Chem. Lett. 2004, 14, 2137. 
 (88) Owen, D. J.; Alexandrov, K.; Rostkova, E.; Scheidig, A. J.; Goody, R. S.; 
Waldmann, H. Angew. Chem. Int. Ed. 1999, 38, 509. 
 (89) Thomä, N. H.; Iakovenko, A.; Owen, D.; Scheidig, A. S.; Waldmann, H.; 
Goody, R. S.; Alexandrov, K. Biochemistry 2000, 39, 12043. 
 (90) Kim; Kleckley, T. S.; Wiemer, A. J.; Holstein, S. A.; Hohl, R. J.; Wiemer, D. 
F. J. Org. Chem. 2004, 69, 8186. 
 (91) Chen, A. P. C.; Chen, Y.-H.; Liu, H.-P.; Li, Y.-C.; Chen, C.-T.; Liang, P.-H. J. 
Am. Chem. Soc. 2002, 124, 15217. 
 (92) Dursina, B.; Reents, R.; Delon, C.; Wu, Y.; Kulharia, M.; Thutewohl, M.; 
Veligodsky, A.; Kalinin, A.; Evstifeev, V.; Ciobanu, D.; Szedlacsek, S. E.; Waldmann, 
H.; Goody, R. S.; Alexandrov, K. J. Am. Chem. Soc. 2006, 128, 2822. 
 (93) Das, D.; Tnimov, Z.; Nguyen, U. T. T.; Thimmaiah, G.; Lo, H.; Abankwa, D.; 
Wu, Y.; Goody, R. S.; Waldmann, H.; Alexandrov, K. ChemBioChem 2012, 13, 674. 
 (94) Chehade, K. A. H.; Kiegiel, K.; Isaacs, R. J.; Pickett, J. S.; Bowers, K. E.; 
Fierke, C. A.; Andres, D. A.; Spielmann, H. P. J. Am. Chem. Soc. 2002, 124, 8206. 
 (95) Rawat, D. S.; Krzysiak, A. J.; Gibbs, R. A. J. Org. Chem. 2008, 73, 1881. 
 (96) Subramanian, T.; Pais, J. E.; Liu, S.; Troutman, J. M.; Suzuki, Y.; Leela 
Subramanian, K.; Fierke, C. A.; Andres, D. A.; Spielmann, H. P. Biochemistry 2012, 
51, 8307. 
 (97) Nguyen, U. T. T.; Guo, Z.; Delon, C.; Wu, Y.; Deraeve, C.; Franzel, B.; Bon, 
R. S.; Blankenfeldt, W.; Goody, R. S.; Waldmann, H.; Wolters, D.; Alexandrov, K. Nat. 
Chem. Biol. 2009, 5, 227. 
 (98) Scott Reid, T.; Terry, K. L.; Casey, P. J.; Beese, L. S. J. Mol. Biol. 2004, 343, 
417. 
 (99) Kho, Y.; Kim, S. C.; Jiang, C.; Barma, D.; Kwon, S. W.; Cheng, J.; 
Jaunbergs, J.; Weinbaum, C.; Tamanoi, F.; Falck, J.; Zhao, Y. Proc. Natl. Acad. Sci. 
USA. 2004, 101, 12479. 
 (100) Rose, M. W.; Rose, N. D.; Boggs, J.; Lenevich, S.; Xu, J.; Barany, G.; 
Distefano, M. D. J. Pept. Res. 2005, 65, 529. 
 (101) DeGraw, A. J.; Palsuledesai, C.; Ochocki, J. D.; Dozier, J. K.; 
Lenevich, S.; Rashidian, M.; Distefano, M. D. Chem. Biol. Drug Des. 2010, 76, 460. 
 (102) Charron, G.; Tsou, L. K.; Maguire, W.; Yount, J. S.; Hang, H. C. Mol. 
 170
BioSyst. 2011, 7, 67. 
 (103) Charron, G.; Li, M. M. H.; MacDonald, M. R.; Hang, H. C. Proc. Natl. 
Acad. Sci. USA. 2013, 110, 11085. 
 (104) Liu, X.-h.; Suh, D.-Y.; Call, J.; Prestwich, G. D. Bioconjugate Chem. 
2004, 15, 270. 
 (105) Lin, H. P.; Hsu, S. C.; Wu, J. C.; Sheen, I. J.; Yan, B. S.; Syu, W. J. J. 
Gen. Virol. 1999, 80, 91. 
 (106) Baron, R.; Fourcade, E.; Lajoie-Mazenc, I.; Allal, C.; Couderc, B.; 
Barbaras, R.; Favre, G.; Faye, J.-C.; Pradines, A. Proc. Natl. Acad. Sci. USA. 2000, 97, 
11626. 
 (107) Troutman, J. M.; Roberts, M. J.; Andres, D. A.; Spielmann, H. P. 
Bioconjugate Chem. 2005, 16, 1209. 
 (108) Onono, F. O.; Morgan, M. A.; Spielmann, H. P.; Andres, D. A.; 
Subramanian, T.; Ganser, A.; Reuter, C. W. M. Mol. Cell. Proteomics 2010, 9, 742. 
 (109) Caplin, B. E.; Hettich, L. A.; Marshall, M. S. Biochim. Biophys. Acta 
1994, 1205, 39. 
 (110) Pompliano, D. L.; Gomez, R. P.; Anthony, N. J. J. Am. Chem. Soc. 
1992, 114, 7945. 
 (111) Cassidy, P. B.; Dolence, J. M.; Poulter, C. D. Methods Enzymol. 1995, 
250, 30. 
 (112) Hougland, J. L.; Hicks, K. A.; Hartman, H. L.; Kelly, R. A.; Watt, T. J.; 
Fierke, C. A. J. Mol. Biol. 2010, 395, 176. 
 (113) Parker, L. L.; Brueggemeier, S. B.; Rhee, W. J.; Wu, D.; Kent, S. B. H.; 
Kron, S. J.; Palecek, S. P. Analyst 2006, 131, 1097. 
 (114) Kress, J.; Zanaletti, R.; Amour, A.; Ladlow, M.; Frey, J. G.; Bradley, M. 
Chem. Eur. J. 2002, 8, 3769. 
 (115) Hosokawa, A.; Wollack, J.; Zhang, Z.; Chen, L.; Barany, G.; Distefano, 
M. Int. J. Pept. Res. Ther. 2007, 13, 345. 
 (116) Maurer-Stroh, S.; Koranda, M.; Benetka, W.; Schneider, G.; Sirota, F. 
L.; Eisenhaber, F. PLoS Comput. Biol. 2007, 3, e66. 
 (117) Gaon, I.; Turek, T. C.; Weller, V. A.; Edelstein, R. L.; Singh, S. K.; 
Distefano, M. D. J. Org. Chem. 1996, 61, 7738. 
 (118) Winkler, D. H.; Andresen, H.; Hilpert, K. Methods Mol. Biol. 2011, 
723, 105. 
 (119) Hartman, H. L.; Hicks, K. A.; Fierke, C. A. Biochemistry 2005, 44, 
15314. 
 (120) Hougland, J. L.; Lamphear, C. L.; Scott, S. A.; Gibbs, R. A.; Fierke, C. 
A. Biochemistry 2009, 48, 1691. 
 171
 (121) Reinicke, A. T.; Hutchinson, J. L.; Magee, A. I.; Mastroeni, P.; 
Trowsdale, J.; Kelly, A. P. J. Biol. Chem. 2005, 280, 14620. 
 (122) Price, C. T. D.; Al-Quadan, T.; Santic, M.; Jones, S. C.; Abu Kwaik, Y. 
J. Exp. Med. 2010, 207, 1713. 
 (123) Ivanov, S. S.; Charron, G.; Hang, H. C.; Roy, C. R. J. Biol. Chem. 2010, 
285, 34686. 
 (124) Zeng, Q.; Si, X.; Horstmann, H.; Xu, Y.; Hong, W.; Pallen, C. J. J. Biol. 
Chem. 2000, 275, 21444. 
 (125) Nishimura, A.; Linder, M. E. Mol. Cell. Biol. 2013, 33, 1417. 
 (126) Yap, M. C.; Kostiuk, M. A.; Martin, D. D. O.; Perinpanayagam, M. A.; 
Hak, P. G.; Siddam, A.; Majjigapu, J. R.; Rajaiah, G.; Keller, B. O.; Prescher, J. A.; 
Wu, P.; Bertozzi, C. R.; Falck, J. R.; Berthiaume, L. G.. J. Lipid Res. 2010, 51, 1566. 
 (127) Hougland, J. L.; Gangopadhyay, S. A.; Fierke, C. A. J. Biol. Chem. 
2012, 287, 38090. 
 (128) Gangopadhyay, S. A.; Losito, E. L.; Hougland, J. L. Biochemistry 2014, 
53, 434. 
 (129) Gilleron, P.; Millet, R.; Houssin, R.; Wlodarczyk, N.; Farce, A.; 
Lemoine, A.; Goossens, J. F.; Chavatte, P.; Pommery, N.; Hénichart, J. P. Eur. J. Med. 
Chem. 2006, 41, 745. 
 (130) Santagada, V.; Caliendo, G.; Severino, B.; Lavecchia, A.; Perissutti, E.; 
Fiorino, F.; Zampella, A.; Sepe, V.; Califano, D.; Santelli, G.; Novellino, E. J. Med. 
Chem. 2006, 49, 1882. 
 (131) Maurer-Stroh, S.; Eisenhaber, F. Genome Biol. 2005, 6, R55. 
 (132) Krzysiak, A. J.; Rawat, D. S.; Scott, S. A.; Pais, J. E.; Handley, M.; 
Harrison, M. L.; Fierke, C. A.; Gibbs, R. A. ACS Chem. Biol. 2007, 2, 385. 
 (133) Chan, L. N.; Hart, C.; Guo, L.; Nyberg, T.; Davies, B. S. J.; Fong, L. G.; 
Young, S. G.; Agnew, B. J.; Tamanoi, F. Electrophoresis 2009, 30, 3598. 
 (134) Palsuledesai, C. C.; Ochocki, J. D.; Markowski, T. W.; Distefano, M. D. 
Mol. BioSyst. 2014, 10, 1094. 
 (135) Hannoush, R. N.; Sun, J. Nat. Chem. Biol. 2010, 6, 498. 
 (136) Wollack, J. W.; Silverman, J. M.; Petzold, C. J.; Mougous, J. D.; 
Distefano, M. D. ChemBioChem 2009, 10, 2934. 
 
 
